{"gene":"NSD2","run_date":"2026-04-29T11:37:57","timeline":{"discoveries":[{"year":1998,"finding":"MMSET (NSD2) was identified as a novel gene disrupted by the t(4;14)(p16.3;q32.3) translocation in multiple myeloma. The long form (1365 aa) contains HMG box, hath region, 4 PHD fingers, and a SET domain, while a short form (647 aa) contains the HMG box and hath region. The translocation results in IgH/MMSET hybrid transcripts and overexpression from endogenous promoters.","method":"Molecular cloning, RT-PCR, domain analysis, translocation breakpoint mapping","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — foundational discovery paper, highly cited, multiple molecular methods","pmids":["9787135"],"is_preprint":false},{"year":2001,"finding":"A mRNA initiated within the middle intron of WHSC1/MMSET encodes RE-IIBP, a protein containing a SET domain and two PHD-type zinc fingers that specifically binds the IL-5 response element RE-II and represses IL-5 transcription when expressed in activated T cells.","method":"Expression cloning, EMSA, 5'-RACE, transfection reporter assays, luciferase reporter","journal":"American journal of respiratory cell and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 — direct functional assays but single lab","pmids":["11152655"],"is_preprint":false},{"year":2005,"finding":"MMSET I isoform represses transcription of a chromatin-embedded reporter gene in a dose-dependent manner and specifically recruits HDAC1 and mSin3b (but not HDAC2 or HDAC4) as shown by co-immunoprecipitation; HDAC inhibitor trichostatin A reduces repression activity.","method":"Co-immunoprecipitation, transcriptional reporter assays, HDAC inhibitor treatment","journal":"British journal of haematology","confidence":"Medium","confidence_rationale":"Tier 2-3 — co-IP plus functional reporter assay, single lab","pmids":["16197452"],"is_preprint":false},{"year":2005,"finding":"All transcripts from the WHSC1/MMSET/NSD2 locus are uniformly overexpressed in t(4;14)+ myeloma patients. GFP-tagged MMSET I and II localize to the nucleus (not nucleoli), while MB4-2 and MB4-3 breakpoint variant proteins concentrate in nucleoli. FRAP kinetic studies show breakpoint variants are functionally distinct from wild-type proteins. Exon 4a/MMSET III contains a domain that prevents nucleolar localization.","method":"Quantitative RT-PCR, GFP-tagging, fluorescence live-cell imaging, FRAP","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — direct live-cell localization with functional consequence, single lab","pmids":["15677557"],"is_preprint":false},{"year":2007,"finding":"MMSET possesses histone methyltransferase activity for H3K4 and H4K20 in vitro; in cells, MMSET modifies only H4K20. MMSET fused to Gal4 DNA-binding domain represses transcription of a chromatin-embedded reporter, associated with increased H4K20 methylation and loss of histone acetylation. MMSET forms a complex with HDAC1, HDAC2, mSin3a, and the histone demethylase LSD1.","method":"In vitro methyltransferase assay, Gal4-reporter transcription assay, co-immunoprecipitation","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro enzymatic assay combined with co-IP complex identification and functional reporter, replicated across multiple methods","pmids":["18156491"],"is_preprint":false},{"year":2007,"finding":"MMSET knockdown by RNAi and selective disruption of the translocated MMSET allele by gene targeting dramatically reduced colony formation in methylcellulose, caused cell-cycle arrest of adherent MM cells, reduced adhesion to extracellular matrix, and reduced tumor formation in xenografts.","method":"RNAi knockdown, gene targeting/knockout, colony formation assay, xenograft mouse model","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal loss-of-function approaches with defined cellular phenotypes","pmids":["17942756"],"is_preprint":false},{"year":2008,"finding":"RE-IIBP (an MMSET isoform) has histone H3K27 methyltransferase activity; SET domain residues C483 and R477 are critical for this activity. RE-IIBP represses transcription via HDAC recruitment mediated by H3K27 methylation, demonstrated at the IL-5 promoter by ChIP showing increased H3K27me, HDAC recruitment, and H3 hypoacetylation.","method":"In vitro HMTase assay, point mutant analysis, ChIP, luciferase reporter","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic assay with active-site mutagenesis plus ChIP and reporter assay","pmids":["18172012"],"is_preprint":false},{"year":2009,"finding":"NSD2 specifically interacts with the DNA-binding domain of androgen receptor (AR) via its HMG domain. Nuclear translocation of both NSD2 and AR is enhanced in the presence of ligand. NSD2 overexpression, but not the SET-domain mutant (ΔSET, HMT-defective), enhances PSA mRNA levels. ChIP showed NSD2 is recruited to the PSA gene enhancer by AR in an agonist-dependent manner.","method":"Co-immunoprecipitation, ChIP, qRT-PCR, domain deletion mutant","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal functional validation with domain mutant and ChIP, single lab","pmids":["19481544"],"is_preprint":false},{"year":2011,"finding":"MMSET (NSD2) is recruited to DNA double-strand breaks (DSBs) via interaction between the MDC1 BRCT domain and phosphorylated Ser102 of MMSET, dependent on the γH2AX-MDC1 pathway. Once recruited, MMSET mediates local H4K20 dimethylation at DSBs, which facilitates 53BP1 accumulation at damage sites.","method":"Co-immunoprecipitation, ChIP, shRNA knockdown, laser-induced DSBs, immunofluorescence","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, direct interaction mapping, published in Nature, highly cited","pmids":["21293379"],"is_preprint":false},{"year":2012,"finding":"MMSET knockdown in prostate cancer cells decreased H3K36me2 and H3K27me3, reduced cell migration and invasion, and blocked EMT. MMSET overexpression in non-transformed RWPE-1 cells promoted invasion and EMT. ChIP showed MMSET binds the TWIST1 locus and increases H3K36me2, directly activating TWIST1 expression, which is the critical mediator of MMSET-driven invasion.","method":"ChIP, shRNA knockdown, overexpression, invasion/migration assays, EMT marker analysis","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — ChIP directly links MMSET to target gene, isogenic gain/loss models, mechanistic rescue experiment","pmids":["22797064"],"is_preprint":false},{"year":2012,"finding":"EZH2 functions upstream of MMSET in a coordinated HMTase axis regulated by a microRNA network. EZH2-mediated H3K27me3 and MMSET-mediated H3K36me2 are coordinately regulated, and the oncogenic functions of EZH2 require MMSET activity.","method":"Genetic knockdown epistasis, microRNA overexpression/inhibition, ChIP","journal":"Molecular cell","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis and ChIP with multiple methods, single lab","pmids":["23159737"],"is_preprint":false},{"year":2012,"finding":"MMSET promotes proliferation of multiple myeloma cells by stimulating c-MYC expression at the post-transcriptional level. MMSET represses miR-126* by binding to its promoter along with the KAP1 corepressor and HDACs, leading to heterochromatic modifications (increased H3K9me3, decreased H3 acetylation). miR-126* targets the 3'-UTR of c-MYC mRNA to inhibit its translation.","method":"miRNA profiling, ChIP, luciferase 3'-UTR reporter assay, miRNA overexpression","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP plus 3'-UTR reporter validates mechanism, single lab","pmids":["22972034"],"is_preprint":false},{"year":2012,"finding":"MMSET plays an important role in class switch recombination (CSR) through its histone methyltransferase activity. MMSET knockdown impaired 53BP1 recruitment to Igh switch regions and decreased germline transcription of switch regions, resulting in defective CSR without affecting cell growth or viability.","method":"shRNA knockdown, CSR assay, 53BP1 recruitment immunofluorescence, germline transcription RT-PCR","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — defined cellular phenotype (CSR) with mechanistic link to 53BP1, single lab","pmids":["23241889"],"is_preprint":false},{"year":2013,"finding":"NSD2 methyltransferase activity is crucial for clonogenicity, adherence, and proliferation of multiple myeloma cells on bone marrow stroma. The PHD domains of NSD2 are required for its cellular activity and recruit NSD2 to oncogenic target gene loci to drive their transcriptional activation.","method":"PHD domain mutants, ChIP, colony formation, proliferation assays, xenograft","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — domain mutagenesis combined with ChIP and functional assays","pmids":["23980095"],"is_preprint":false},{"year":2013,"finding":"NSD2 p.E1099K is an activating mutation that increases H3K36 dimethylation and promotes transformation; NSD2 knockdown selectively inhibits proliferation of NSD2-mutant ALL cell lines and impairs in vivo growth of NSD2-mutant ALL xenografts. Global histone profiling by mass spectrometry identified the distinct H3K36me2 signature of NSD2 hyperactivation.","method":"High-information-content mass spectrometry histone profiling, ectopic expression, shRNA knockdown, xenograft","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1-2 — MS-based chromatin profiling plus gain/loss-of-function in vitro and in vivo, replicated in >1000 cancer genomes","pmids":["24076604"],"is_preprint":false},{"year":2014,"finding":"MMSET overexpression causes a global increase in H3K36me2 and a global reduction of H3K27me3. Despite net decrease in H3K27me3, specific loci show enhanced EZH2 recruitment and become hypermethylated on H3K27. PHD domains of MMSET mediate its chromatin recruitment and are required for these epigenetic changes.","method":"ChIP-seq, shRNA inducible knockdown, PHD domain mutants, xenograft tumor regression","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1-2 — genome-wide ChIP-seq with domain mutants and in vivo validation","pmids":["25188243"],"is_preprint":false},{"year":2014,"finding":"Whsc1 promotes the association of Runx2 and p300 to activate bone-related genes (Osteopontin, Col1a1). Whsc1 suppresses overactivation of these genes via H3K36 trimethylation. Whsc1-/- embryos exhibit defects in ossification, and Whsc1 knockdown in pre-osteoblasts perturbs histone modification patterns at bone-related gene loci.","method":"Co-immunoprecipitation (Runx2/p300 association), ChIP, Whsc1 knockout mouse, siRNA knockdown, bone differentiation assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP plus ChIP plus KO model with skeletal phenotype","pmids":["25188294"],"is_preprint":false},{"year":2016,"finding":"NSD2 catalyzes H3K36 dimethylation via an SN2 mechanism where methyl transfer is the first irreversible chemical step. The transition state is a late, asymmetric nucleophilic displacement with bond separation from the leaving group at 2.53 Å and bond making to the attacking nucleophile at 2.10 Å. NSD2 preferentially catalyzes H3K36 dimethylation over monomethylation.","method":"Kinetic isotope effect measurements, quantum chemical/computational modeling, in vitro enzymatic assay with nucleosome substrate","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — rigorous in vitro mechanistic chemistry with KIE measurements and quantum modeling","pmids":["26787850"],"is_preprint":false},{"year":2016,"finding":"MMSET is required for efficient non-homologous end joining (NHEJ) and homologous recombination (HR). Loss of MMSET leads to loss of expression of several DNA repair proteins and decreased recruitment of DNA repair proteins to DSB sites. MMSET-high cells repair DNA damage at enhanced rate compared to MMSET-low isogenic cells.","method":"NHEJ/HR reporter assays, immunofluorescence of DNA repair factor recruitment, isogenic MM cell line pairs, xenograft","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — isogenic cell lines, multiple repair assays, defined molecular phenotype","pmids":["27109101"],"is_preprint":false},{"year":2016,"finding":"MMSET is degraded during S phase in a CRL4(Cdt2)- and proteasome-dependent manner. MMSET depletion causes defects in DNA replication and decreased association of pre-replication complex (pre-RC) factors with chromatin, indicating a role for MMSET in normal DNA replication.","method":"Cell synchronization, co-immunoprecipitation, chromatin fractionation, DNA fiber assay","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 2 — direct mechanistic link between protein stability regulation and DNA replication phenotype, single lab","pmids":["26771714"],"is_preprint":false},{"year":2016,"finding":"NSD2 (methyltransferase-active) is recruited to promoters of glucose metabolic enzyme genes (HK2, G6PD, TIGAR) and methylates H3K36me2 at these loci, coordinately upregulating their expression to drive pentose phosphate pathway activity and endocrine resistance in breast cancer. Methylase-defective NSD2 mutant cannot drive resistance.","method":"ChIP, gene expression profiling, methylase-dead mutant, xenograft, PPP activity assay","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP with catalytic mutant control demonstrates direct epigenetic regulation of metabolic genes","pmids":["27164560"],"is_preprint":false},{"year":2017,"finding":"AKT phosphorylates WHSC1 at S172 upon PTEN loss, preventing its degradation by CRL4Cdt2 E3 ligase. Increased WHSC1 transcriptionally upregulates RICTOR (mTORC2 component) to further enhance AKT activity, forming a feedback loop. WHSC1 also positively regulates Rac1 transcription to increase tumor cell motility.","method":"In vivo mouse PCa model (PTEN-null + WHSC1 overexpression), genetic ablation, phosphorylation mapping, co-immunoprecipitation, ChIP","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 — in vivo genetic model combined with biochemical phosphorylation mapping and multiple orthogonal methods","pmids":["28319045"],"is_preprint":false},{"year":2017,"finding":"DICER mediates the recruitment of MMSET to UV-induced DNA damage sites. MMSET is required for efficient nucleotide excision repair (NER) by catalyzing H4K20me2 at DNA damage sites, which facilitates recruitment of the NER factor XPA.","method":"Immunofluorescence at UV damage sites, MMSET knockdown, ChIP, XPA recruitment assay","journal":"The Journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization experiments with functional NER assay and mechanistic link to XPA","pmids":["29233865"],"is_preprint":false},{"year":2018,"finding":"The NSD2 E1099K mutation alters enzyme/substrate binding and enhances the rate of H3K36 methylation in vitro. E1099K cells exhibit increased H3K36me2, reduced H3K27me3 (particularly on H3.1-containing nucleosomes), reduced apoptosis, and enhanced proliferation, clonogenicity, adhesion, migration, and brain invasion in xenografts.","method":"Gene-edited isogenic cell lines, in vitro enzymatic assay, transcriptional profiling, xenograft","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 — gene editing plus in vitro kinetics plus comprehensive phenotyping","pmids":["30171259"],"is_preprint":false},{"year":2019,"finding":"DNA DSBs promote NSD2-mediated dimethylation of PTEN at K349; this methylation is recognized by the tudor domain of 53BP1 to recruit PTEN to DNA-damage sites, governing efficient DSB repair partly through dephosphorylation of γH2AX. ATM-dependent phosphorylation of T/S398-PTEN promotes PTEN interaction with MDC1 upstream of NSD2 activity.","method":"Co-immunoprecipitation, mass spectrometry methylation mapping, site-directed mutagenesis, in vitro methylation assay, xenograft","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical methylation mapping with mutagenesis, in vitro assay, and in vivo validation","pmids":["31217297"],"is_preprint":false},{"year":2019,"finding":"NSD2 promotes tumor angiogenesis by methylating STAT3 at K163; mass spectrometry and site-directed mutagenesis confirmed this methylation site. K163R STAT3 mutant shows attenuated activation and angiogenic function. NSD2 promotes STAT3 activation through a methylation-phosphorylation regulation pattern, driving VEGFA expression.","method":"Co-immunoprecipitation, mass spectrometry, site-directed mutagenesis (K163R), in vitro methylation assay, angiogenesis assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 1-2 — MS-confirmed methylation site with mutagenesis validation, single lab","pmids":["33742125"],"is_preprint":false},{"year":2019,"finding":"NSD2 overexpression drives chromatin and transcriptional changes linked to oncogene activation within insulated topological domains. NSD2-driven expansion of H3K36me2 leads to alterations in H3K27ac and CTCF binding within H3K36me2-enriched chromatin, and differentially expressed genes are significantly enriched within the same insulated domain as altered H3K27ac and CTCF peaks.","method":"ChIP-seq, Hi-C/3D genome organization, isogenic cell lines (high vs. low NSD2), logistic regression modeling","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — genome-wide multi-omics in isogenic lines, single lab","pmids":["31649247"],"is_preprint":false},{"year":2019,"finding":"PARP1 directly interacts with NSD2 (identified by BioID proximity labeling and MS). Upon oxidative stress, PARP1 PARylates NSD2, which significantly reduces NSD2 histone methyltransferase activity in vitro and inhibits NSD2 binding to nucleosomes and its recruitment to NSD2-regulated gene loci.","method":"BioID proximity labeling, mass spectrometry, in vitro methyltransferase assay, nucleosome binding assay, ChIP","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — interactome discovery plus in vitro enzymatic assay validation plus ChIP, multiple orthogonal methods","pmids":["31248990"],"is_preprint":false},{"year":2019,"finding":"Whsc1 (NSD2) is required for follicular helper T (Tfh) cell differentiation. CD28 signaling induces Nsd2 expression, which is required for Bcl6 expression as early as the first cell division after T cell activation. Nsd2 deficiency impairs Tfh generation, germinal center response, and virus clearance. Ectopic Bcl6 expression rescues the Tfh defect of Nsd2 KO cells.","method":"Conditional knockout, Bcl6 rescue experiment, germinal center assays, flow cytometry","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 — conditional KO with genetic rescue establishing epistatic relationship","pmids":["31636135"],"is_preprint":false},{"year":2019,"finding":"Whsc1 has a dual role in pluripotency exit and germ layer specification in mouse embryonic stem cells. Whsc1 binds to enhancers of mesendodermal regulators (Gata4, Brachyury, Gata6, Foxa2) together with Brd4 to activate their expression. Notably, these functions are independent of Whsc1 methyltransferase activity.","method":"Conditional depletion, ChIP, co-immunoprecipitation with Brd4, directed differentiation assays, methyltransferase-dead mutant","journal":"Nature cell biology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and catalytic mutant establish non-enzymatic function, single lab","pmids":["31235934"],"is_preprint":false},{"year":2020,"finding":"NSD2 knockdown in primary human fibroblasts induces cellular senescence via RB-mediated downregulation of cell cycle-related genes. NSD2 is enriched at gene bodies of actively transcribed genes including cell cycle-related genes, and NSD2 loss decreases H3K36me3 at these loci. Serum stimulation upregulates NSD2 and induces cell cycle gene expression.","method":"RNAi screen, ChIP, transcriptome analysis, senescence assays (SA-β-gal, mitochondrial mass)","journal":"Aging cell","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP links NSD2 occupancy to H3K36me3 at target loci with functional senescence phenotype","pmids":["32573059"],"is_preprint":false},{"year":2020,"finding":"MMSET promotes H3K36me2 at deprotected telomeres through its SET-domain catalytic activity, and this promotes classical (Ligase4-dependent) NHEJ at deprotected telomeres. MMSET-dependent H3K36me2 levels directly correlate with NHEJ efficiency; MMSET depletion does not affect upstream DDR recognition but acts downstream at the repair step.","method":"Methyltransferase screen, MMSET knockdown, telomere dysfunction assay, ChIP, Ligase4-dependent NHEJ assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — direct correlation between enzymatic activity and NHEJ in defined assay system","pmids":["32472076"],"is_preprint":false},{"year":2021,"finding":"Cryo-EM structure of NSD2 bound to the nucleosome reveals that nucleosomal DNA is partially unwrapped to facilitate NSD2 access to H3K36. NSD2 interacts with DNA, H2A, and H3. The autoinhibitory loop changes conformation upon nucleosome binding to accommodate H3 in the substrate-binding cleft. E1099K and T1150A oncogenic mutations increase catalytic turnover by destabilizing interactions that keep the autoinhibitory loop closed.","method":"Cryo-electron microscopy structure determination, kinetic analysis, molecular dynamics simulation","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — high-resolution cryo-EM structure with functional kinetic validation and MD simulation of oncogenic mutations","pmids":["34782608"],"is_preprint":false},{"year":2021,"finding":"NSD2 PWWP1 domain occupies a canonical H3K36me2-binding pocket. A chemical probe (UNC6934) targeting PWWP1 antagonizes its interaction with nucleosomal H3K36me2 and induces accumulation of endogenous NSD2 in the nucleolus, phenocopying localization defects of NSD2 isoforms lacking PWWP1 (as occur in t(4;14) MM). Mutations in other NSD2 chromatin reader domains also increase NSD2 nucleolar localization.","method":"Chemical probe (UNC6934), co-crystal structure of PWWP1/probe, cellular NSD2 localization by imaging, nucleosome-binding assays","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus chemical probe with functional cellular localization consequence","pmids":["34782742"],"is_preprint":false},{"year":2021,"finding":"NSD2 E1099K mutation drives glucocorticoid resistance in pediatric ALL by causing H3K27me3 accumulation at the NR3C1 (glucocorticoid receptor) promoter, repressing GR expression and blocking GR autoactivation. PRC2 inhibitors remove this H3K27me3, restore NR3C1 expression, and reverse glucocorticoid resistance in vitro and in vivo.","method":"High-throughput drug screening, CRISPR correction of E1099K, ChIP-seq, PRC2 inhibitor treatment, PDX model","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 2 — CRISPR isogenic correction, genome-wide ChIP-seq, PDX validation, clear mechanistic pathway","pmids":["34417224"],"is_preprint":false},{"year":2021,"finding":"NSD2 interacts with SMARCA2 (SWI/SNF ATPase subunit) in a non-canonical, SWI/SNF complex-independent manner. The NSD2-SMARCA2 complex is mapped to the PTP4A3 promoter by ChIP, leading to focal H3K36me2 increase and transcriptional activation of PTP4A3, which maintains MYC expression. BET inhibitor PFI-3 displaces NSD2 from the PTP4A3 promoter.","method":"SILAC-based mass spectrometry interactome, co-immunoprecipitation, ChIP, RNA-seq","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — MS-based interactome validated by co-IP and ChIP, single lab","pmids":["33602783"],"is_preprint":false},{"year":2021,"finding":"NSD2 via H3K36me2 catalysis cooperates with oncogenic KRAS signaling to drive lung adenocarcinoma (LUAD) pathogenesis in vivo. NSD2E1099K expression accelerates malignant tumor progression in KRAS-driven LUAD mouse models. Pathologic H3K36me2 generation amplifies transcriptional output of KRAS and complementary oncogenic gene expression programs.","method":"In vivo LUAD mouse model, CRISPRi-based knockdown, PDX model, MEK inhibitor combination, ChIP-seq","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1-2 — in vivo genetic model with CRISPRi, PDX, and ChIP-seq, rigorous epistasis with KRAS pathway","pmids":["34555356"],"is_preprint":false},{"year":2021,"finding":"WHSC1 loss impairs IFN-γ-stimulated antitumor immunity by transcriptionally downregulating MHC-I machinery without affecting PD-L1. WHSC1 directly interacts with NLRC5 to promote MHC-I gene expression. IFN-γ/STAT1 signaling stimulates WHSC1 expression, which in turn promotes NLRC5-dependent antigen presentation.","method":"Co-immunoprecipitation (WHSC1-NLRC5), shRNA knockdown, CRC organoids, xenografts, Apcmin/+ mouse model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — direct interaction identified by co-IP, multiple in vivo models, defined immune phenotype","pmids":["35230972"],"is_preprint":false},{"year":2021,"finding":"Loss-of-function and missense NSD2 variants cause reduced H3K36 methyltransferase activity in vitro; missense variants fail to reconstitute H3K36me2 in NSD2 knockout cells. Structural modeling indicates interference with NSD2 folding and function for missense variants in known structural domains.","method":"In vitro methylation assay, NSD2 KO cell complementation, in silico structural modeling","journal":"Genetics in medicine","confidence":"Medium","confidence_rationale":"Tier 1-2 — in vitro enzyme assay with KO complementation, multiple variants tested","pmids":["33941880"],"is_preprint":false},{"year":2022,"finding":"Nsd2 (but not Nsd1 or Setd2) is required for adipogenesis; depletion of Nsd2 in preadipocytes phenocopies H3.3K36M effects by increasing H3K27me3 to prevent induction of C/EBPα and PPARγ target genes. In differentiated adipocytes, Nsd2 loss does not affect tissue weight but leads to BAT whitening and insulin resistance in WAT.","method":"shRNA knockdown of Nsd2/Nsd1/Setd2 (selective comparison), H3.3K36M expression, adipogenesis assays, in vivo mouse models, ChIP","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — selective comparison among paralogues establishes specificity, in vitro and in vivo validation","pmids":["29728617"],"is_preprint":false},{"year":2022,"finding":"Nsd2 deficiency in mouse spermatogenic cells reduces H3K36me2 and H3K36me3 genome-wide, with H3K36me2 occupancy positively correlating with germline gene expression. Nsd2 loss leads to H4K16ac elevation through interaction with PSMA8 (which regulates acetylated histone degradation), impairs EP300-induced H4K5/8ac and BRDT-mediated histone eviction, causing histone retention in spermatozoa.","method":"Conditional knockout, ChIP-seq, co-immunoprecipitation (NSD2-PSMA8), spermatogenesis assays, fertility phenotype","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 — conditional KO with ChIP-seq and co-IP defining mechanistic cascade, single lab","pmids":["35736136"],"is_preprint":false},{"year":2022,"finding":"Nsd2 upregulates CXCR4 expression via H3K36me2 modification to promote regulatory T cell recruitment to the maternal-fetal interface. Nsd2 conditional KO in Tregs specifically reduces Treg levels at the decidua and causes fetal loss without affecting systemic Treg development or function.","method":"Conditional knockout, ChIP (H3K36me2 at CXCR4 locus), Treg recruitment assay, pregnancy model","journal":"Cellular & molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 — conditional KO with ChIP and defined cellular recruitment phenotype, single lab","pmids":["35322173"],"is_preprint":false},{"year":2023,"finding":"NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in prostate cancer. Tumor-specific AR enhancers critically rely on NSD2's H3K36 dimethyltransferase activity. NSD2 inactivation disrupts over 65% of AR cistrome; NSD2-dependent AR sites harbor a chimeric FOXA1:AR half-motif exclusive to tumor-specific enhancers.","method":"ChIP-seq (AR, NSD2, H3K36me2), NSD2 inactivation, AR cistrome analysis, PROTAC degrader, patient specimens","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — genome-wide ChIP-seq with genetic inactivation and PROTAC degrader, validated in patient specimens","pmids":["39251788"],"is_preprint":false},{"year":2023,"finding":"NSD2 is selectively degraded by a PROTAC (UNC8153) through a novel mechanism via a simple warhead, and separately by UNC8732 through FBXO22 recruitment (FBXO22's C326 is engaged by an aldehyde metabolite). Both degraders reduce H3K36me2, suppress MM cell adhesion and proliferation, and cause apoptosis and drug resistance reversal in NSD2-mutant ALL cells.","method":"PROTAC degradation assay, proteasome/cereblon/FBXO22 dependence assays, H3K36me2 western blot, anti-proliferative assays","journal":"Journal of the American Chemical Society / Nature chemical biology","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic E3 ligase identification with defined biochemical readout","pmids":["36976643","38965384"],"is_preprint":false},{"year":2024,"finding":"Systematic perturbation of H3K36 methyltransferases established that NSD2 (along with NSD1) is responsible for deposition of broad intergenic H3K36me2 domains, while NSD3 deposits H3K36me2 peaks on active promoters and enhancers. A hierarchy of K36MT activities was determined: NSD1 > NSD2 > NSD3 > ASH1L for intergenic H3K36me1/2 deposition.","method":"CRISPR knockout of individual K36MTs, ChIP-seq (H3K36me1/2/3), RNA-seq, mouse mesenchymal stem cells","journal":"Genome biology","confidence":"High","confidence_rationale":"Tier 2 — systematic parallel KO comparisons with genome-wide ChIP-seq establishing functional hierarchy","pmids":["39390582"],"is_preprint":false}],"current_model":"NSD2 (MMSET/WHSC1) is a histone H3K36 di-methyltransferase whose SET domain catalyzes an SN2 methyl-transfer reaction on nucleosomes via an autoinhibitory loop that opens upon nucleosome engagement; it is recruited to chromatin through its PWWP1 domain (which reads H3K36me2) and PHD domains, and its overexpression or activating mutations (e.g., E1099K, T1150A) drive global H3K36me2 expansion with reciprocal H3K27me3 reduction, reprogramming gene expression to promote oncogenesis, while in the DNA damage response it is recruited to DSBs via γH2AX-MDC1 interaction to locally deposit H4K20me2 (facilitating 53BP1 recruitment) and H3K36me2 (promoting NHEJ/HR), and it also non-histone substrates including PTEN-K349 and STAT3-K163, interacts with complexes including HDAC1/HDAC2/LSD1/mSin3a, SMARCA2, and NLRC5, and is regulated post-translationally by AKT-mediated phosphorylation at S172 (blocking CRL4Cdt2-dependent degradation) and PARP1-mediated PARylation (reducing its methyltransferase activity and chromatin binding)."},"narrative":{"teleology":[{"year":1998,"claim":"Identification of NSD2 as the gene disrupted by the t(4;14) translocation in multiple myeloma established it as a candidate oncogene and revealed its multi-domain architecture (HMG, PHD fingers, SET domain).","evidence":"Molecular cloning and translocation breakpoint mapping in MM patient samples","pmids":["9787135"],"confidence":"High","gaps":["Enzymatic activity of the SET domain was unknown","Oncogenic mechanism was not established"]},{"year":2005,"claim":"Functional loss-of-function studies and localization experiments demonstrated that NSD2 overexpression is required for myeloma cell proliferation and colony formation, and that it acts as a transcriptional repressor recruiting HDAC1/mSin3b, while breakpoint-variant isoforms show aberrant nucleolar localization.","evidence":"RNAi knockdown, gene targeting of translocated allele, co-immunoprecipitation, reporter assays, GFP-tagging and FRAP in MM cells","pmids":["16197452","17942756","15677557"],"confidence":"High","gaps":["Histone substrate specificity was unresolved","Whether repression required catalytic activity was unclear"]},{"year":2007,"claim":"Biochemical characterization revealed NSD2 possesses histone methyltransferase activity (H4K20 in cells, H3K4/H4K20 in vitro) and forms a repressive complex with HDAC1, HDAC2, mSin3a, and LSD1, while an alternatively transcribed isoform (RE-IIBP) showed H3K27 methyltransferase activity.","evidence":"In vitro methyltransferase assays, co-immunoprecipitation, Gal4-reporter assays, active-site mutagenesis","pmids":["18156491","18172012"],"confidence":"High","gaps":["The primary physiological histone substrate (H3K36me2) had not yet been identified","Specificity for H3K27 was later disputed"]},{"year":2011,"claim":"Discovery of NSD2 recruitment to DNA double-strand breaks via the γH2AX–MDC1 pathway, where it deposits H4K20me2 to facilitate 53BP1 accumulation, established a direct role in the DNA damage response.","evidence":"Co-immunoprecipitation of phospho-S102 NSD2 with MDC1 BRCT domain, laser-induced DSB recruitment, ChIP","pmids":["21293379"],"confidence":"High","gaps":["Whether NSD2 also deposited H3K36me2 at DSBs was not shown","Relative contributions to NHEJ vs HR were unclear"]},{"year":2012,"claim":"Multiple studies converged on H3K36me2 as NSD2's principal mark in cancer, showing that NSD2 overexpression causes global H3K36me2 gain with reciprocal H3K27me3 loss, directly activates TWIST1 to drive EMT, represses miR-126* to upregulate c-MYC, and is required for class switch recombination via 53BP1 recruitment to Igh switch regions.","evidence":"ChIP at target loci (TWIST1, miR-126*), isogenic gain/loss-of-function in prostate and MM cells, CSR assays, epistasis with EZH2","pmids":["22797064","22972034","23241889","23159737"],"confidence":"High","gaps":["Genome-wide distribution of H3K36me2 changes was not yet mapped","Whether H3K36me2 was primary or secondary to other marks was debated"]},{"year":2013,"claim":"Discovery of the E1099K activating mutation in pediatric ALL, confirmed by mass spectrometry histone profiling, established that NSD2 gain-of-function through point mutations (not just translocation/overexpression) drives oncogenesis via H3K36me2 expansion.","evidence":"Mass spectrometry histone profiling across >1000 cancer genomes, shRNA knockdown, xenograft","pmids":["24076604"],"confidence":"High","gaps":["Structural basis for E1099K hyperactivation was unknown","Therapeutic vulnerabilities of NSD2-mutant cancers were unexplored"]},{"year":2014,"claim":"Genome-wide ChIP-seq revealed that NSD2 overexpression redistributes H3K36me2 globally while paradoxically enhancing EZH2 recruitment at specific loci, and that PHD domains mediate NSD2 chromatin recruitment and are required for these epigenetic changes and in vivo tumorigenesis.","evidence":"ChIP-seq in isogenic MM cell lines, PHD domain mutants, xenograft tumor regression","pmids":["25188243"],"confidence":"High","gaps":["How PHD domains select target loci was unresolved","3D genome consequences were not examined"]},{"year":2016,"claim":"Kinetic isotope effect measurements established that NSD2 catalyzes H3K36 dimethylation via an SN2 mechanism with a late asymmetric transition state, preferring dimethylation over monomethylation, while functional studies showed NSD2 is required for both NHEJ and HR and is regulated by CRL4Cdt2-dependent S-phase degradation.","evidence":"KIE measurements, quantum chemical modeling, NHEJ/HR reporter assays in isogenic MM lines, cell synchronization and degradation assays","pmids":["26787850","27109101","26771714"],"confidence":"High","gaps":["Structural basis for nucleosome recognition was unknown","How degradation is counteracted in cancer was unclear"]},{"year":2017,"claim":"AKT-mediated phosphorylation at S172 was shown to stabilize NSD2 by blocking CRL4Cdt2-dependent degradation, creating a positive feedback loop through NSD2-driven RICTOR transcription that amplifies AKT/mTORC2 signaling in PTEN-null prostate cancer.","evidence":"In vivo PTEN-null mouse prostate cancer model, phosphorylation mapping, co-immunoprecipitation, ChIP","pmids":["28319045"],"confidence":"High","gaps":["Whether other kinases phosphorylate NSD2 at additional sites was unknown","Therapeutic targeting of this feedback loop was not tested"]},{"year":2019,"claim":"NSD2 was found to methylate non-histone substrates—PTEN at K349 (read by 53BP1 tudor domain for DSB repair) and STAT3 at K163 (activating angiogenic signaling)—while PARP1-mediated PARylation was discovered to inhibit NSD2 catalytic activity and chromatin binding, and NSD2 was shown to have catalytic-activity-independent scaffolding roles (with BRD4 at mesendodermal enhancers) and immune functions (Tfh cell differentiation via Bcl6).","evidence":"MS-based methylation mapping, site-directed mutagenesis, in vitro methylation assays, BioID proximity labeling, conditional knockout with genetic rescue, ChIP","pmids":["31217297","33742125","31248990","31235934","31636135","31649247"],"confidence":"High","gaps":["Full non-histone substrate repertoire was unknown","Whether scaffolding and enzymatic functions are separable in vivo was untested"]},{"year":2021,"claim":"Cryo-EM structure of NSD2 bound to the nucleosome revealed the autoinhibitory loop mechanism and how E1099K/T1150A mutations destabilize it, while a chemical probe (UNC6934) targeting the PWWP1 domain confirmed its role in reading H3K36me2 for chromatin retention and showed that PWWP1 antagonism redirects NSD2 to the nucleolus.","evidence":"Cryo-EM at near-atomic resolution, kinetic analysis, MD simulation, co-crystal structure of PWWP1/UNC6934, cellular imaging","pmids":["34782608","34782742"],"confidence":"High","gaps":["Full-length NSD2 structure including all reader domains was not resolved","Whether PWWP1 antagonism is sufficient for therapeutic benefit was untested"]},{"year":2021,"claim":"NSD2 E1099K was shown to drive glucocorticoid resistance in pediatric ALL through H3K27me3 accumulation at the NR3C1 promoter (reversible by PRC2 inhibitors), while NSD2 cooperates with oncogenic KRAS to amplify transcriptional output in lung adenocarcinoma and functions as a requisite subunit of the AR/FOXA1 neo-enhanceosome at tumor-specific prostate cancer enhancers.","evidence":"CRISPR correction of E1099K, ChIP-seq, PRC2 inhibitor in PDX models, KRAS-driven LUAD mouse model, AR cistrome analysis with PROTAC degrader","pmids":["34417224","34555356","39251788"],"confidence":"High","gaps":["Whether NSD2 inhibition synergizes with immunotherapy across cancers is unknown","How NSD2 is recruited to AR/FOXA1 sites mechanistically is incompletely defined"]},{"year":2022,"claim":"NSD2 was established as required for adipogenesis (preventing H3K27me3-mediated silencing of C/EBPα/PPARγ targets), for spermatogenesis (maintaining H3K36me2 and regulating histone eviction via PSMA8 interaction), and for regulatory T cell homing to the maternal-fetal interface via CXCR4 upregulation.","evidence":"Conditional knockouts in preadipocytes, spermatogenic cells, and Tregs; ChIP-seq; co-immunoprecipitation; fertility/pregnancy phenotyping","pmids":["29728617","35736136","35322173"],"confidence":"Medium","gaps":["Whether NSD2's roles in these lineages are catalytic or scaffolding is incompletely resolved","Tissue-specific NSD2 target gene programs are not fully defined"]},{"year":2023,"claim":"Development of PROTAC degraders (UNC8153, UNC8732) demonstrated that targeted NSD2 degradation reduces H3K36me2, suppresses MM cell adhesion/proliferation, and reverses drug resistance in NSD2-mutant ALL, validating NSD2 as a druggable target.","evidence":"PROTAC degradation assays, FBXO22/cereblon dependency mapping, anti-proliferative assays in MM and ALL cells","pmids":["36976643","38965384"],"confidence":"Medium","gaps":["In vivo pharmacokinetics and toxicity profiles are unreported","Selectivity over NSD1/NSD3 in therapeutic settings is uncharacterized"]},{"year":2024,"claim":"Systematic CRISPR knockout of all H3K36 methyltransferases established a functional hierarchy (NSD1 > NSD2 > NSD3 > ASH1L) for intergenic H3K36me2 deposition, with NSD2 being the second-most important enzyme for broad intergenic domains.","evidence":"Individual and combinatorial CRISPR KO of K36MTs, ChIP-seq for H3K36me1/2/3, RNA-seq in mouse mesenchymal stem cells","pmids":["39390582"],"confidence":"High","gaps":["Whether this hierarchy is conserved across all human cell types is untested","Compensation mechanisms among NSD family members are incompletely understood"]},{"year":null,"claim":"Key unresolved questions include the full non-histone substrate repertoire, the structural basis for how reader domains (PHD, PWWP) coordinate locus-specific targeting genome-wide, whether catalytic and scaffolding functions can be therapeutically separated, and the in vivo efficacy and selectivity of NSD2-targeted degraders.","evidence":"","pmids":[],"confidence":"High","gaps":["No full-length NSD2 structure with all reader domains","Comprehensive non-histone substrate profiling has not been performed","In vivo therapeutic index of NSD2-selective degraders or inhibitors is unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[4,6,14,17,23,32,38,44]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[24,25]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,2,9,20,42]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[32,33]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,33]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[3,33]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[8,15,32]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[4,14,15,17,32,44]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[8,18,22,24,31]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,2,9,20,42]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,5,14,23,34,36]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[12,28,37,41]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[19,30]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[16,29,39]}],"complexes":["HDAC1/HDAC2/LSD1/mSin3a repressor complex","AR/FOXA1 neo-enhanceosome"],"partners":["MDC1","PARP1","SMARCA2","NLRC5","BRD4","AR","HDAC1","PTEN"],"other_free_text":[]},"mechanistic_narrative":"NSD2 (MMSET/WHSC1) is a histone H3K36 dimethyltransferase that catalyzes broad intergenic H3K36me2 deposition on nucleosomal substrates via an SN2 methyl-transfer mechanism, with an autoinhibitory loop that opens upon nucleosome engagement to grant access to H3K36; its overexpression or activating mutations (E1099K, T1150A) drive global H3K36me2 expansion with reciprocal H3K27me3 reduction, reprogramming enhancer landscapes, CTCF binding, and gene expression to promote oncogenesis in multiple myeloma, ALL, prostate cancer, and lung adenocarcinoma [PMID:34782608, PMID:24076604, PMID:25188243, PMID:31649247, PMID:34555356]. Beyond histone methylation, NSD2 methylates non-histone substrates including PTEN-K349 (facilitating 53BP1-mediated DSB repair) and STAT3-K163 (promoting angiogenesis), and is recruited to DNA damage sites via γH2AX–MDC1 interaction to deposit H4K20me2 and H3K36me2 that promote NHEJ, HR, and nucleotide excision repair [PMID:21293379, PMID:31217297, PMID:33742125, PMID:27109101, PMID:29233865]. NSD2 also functions in a catalytic-activity-independent manner as a scaffold at enhancers with BRD4 during germ-layer specification, interacts with NLRC5 to drive MHC-I antigen presentation, and serves as a requisite subunit of the AR/FOXA1 neo-enhanceosome at tumor-specific prostate cancer enhancers [PMID:31235934, PMID:35230972, PMID:39251788]. NSD2 protein stability is regulated by CRL4Cdt2-dependent S-phase degradation counteracted by AKT-mediated phosphorylation at S172, and its enzymatic activity is inhibited by PARP1-mediated PARylation [PMID:26771714, PMID:28319045, PMID:31248990]."},"prefetch_data":{"uniprot":{"accession":"O96028","full_name":"Histone-lysine N-methyltransferase NSD2","aliases":["Multiple myeloma SET domain-containing protein","MMSET","Nuclear SET domain-containing protein 2","Protein trithorax-5","Wolf-Hirschhorn syndrome candidate 1 protein"],"length_aa":1365,"mass_kda":152.3,"function":"Histone methyltransferase which specifically dimethylates nucleosomal histone H3 at 'Lys-36' (H3K36me2) (PubMed:19808676, PubMed:22099308, PubMed:27571355, PubMed:29728617, PubMed:33941880). Also monomethylates nucleosomal histone H3 at 'Lys-36' (H3K36me) in vitro (PubMed:22099308). Does not trimethylate nucleosomal histone H3 at 'Lys-36' (H3K36me3) (PubMed:22099308). However, specifically trimethylates histone H3 at 'Lys-36' (H3K36me3) at euchromatic regions in embryonic stem (ES) cells (By similarity). By methylating histone H3 at 'Lys-36', involved in the regulation of gene transcription during various biological processes (PubMed:16115125, PubMed:22099308, PubMed:29728617). In ES cells, associates with developmental transcription factors such as SALL1 and represses inappropriate gene transcription mediated by histone deacetylation (By similarity). During heart development, associates with transcription factor NKX2-5 to repress transcription of NKX2-5 target genes (By similarity). Plays an essential role in adipogenesis, by regulating expression of genes involved in pre-adipocyte differentiation (PubMed:29728617). During T-cell receptor (TCR) and CD28-mediated T-cell activation, promotes the transcription of transcription factor BCL6 which is required for follicular helper T (Tfh) cell differentiation (By similarity). During B-cell development, required for the generation of the B1 lineage (By similarity). During B2 cell activation, may contribute to the control of isotype class switch recombination (CRS), splenic germinal center formation, and the humoral immune response (By similarity). Plays a role in class switch recombination of the immunoglobulin heavy chain (IgH) locus during B-cell activation (By similarity). By regulating the methylation of histone H3 at 'Lys-36' and histone H4 at 'Lys-20' at the IgH locus, involved in TP53BP1 recruitment to the IgH switch region and promotes the transcription of IgA (By similarity) Histone methyltransferase which specifically dimethylates nucleosomal histone H3 at 'Lys-36' (H3K36me2) Histone methyltransferase which specifically dimethylates nucleosomal histone H3 at 'Lys-36' (H3K36me2) (PubMed:22099308). Methylation of histone H3 at 'Lys-27' is controversial (PubMed:18172012, PubMed:22099308). Mono-, di- or tri-methylates histone H3 at 'Lys-27' (H3K27me, H3K27me2 and H3K27me3) (PubMed:18172012). Does not methylate histone H3 at 'Lys-27' (PubMed:22099308). May act as a transcription regulator that binds DNA and suppresses IL5 transcription through HDAC recruitment (PubMed:11152655, PubMed:18172012)","subcellular_location":"Cytoplasm; Nucleus, nucleolus","url":"https://www.uniprot.org/uniprotkb/O96028/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NSD2","classification":"Not Classified","n_dependent_lines":6,"n_total_lines":1208,"dependency_fraction":0.004966887417218543},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"HMGN5","stoichiometry":4.0},{"gene":"NUCKS1","stoichiometry":4.0},{"gene":"EPN2","stoichiometry":0.2},{"gene":"FKBP5","stoichiometry":0.2},{"gene":"HIST2H2BE","stoichiometry":0.2},{"gene":"HMGA1","stoichiometry":0.2},{"gene":"HMGN2","stoichiometry":0.2},{"gene":"MYO1E","stoichiometry":0.2},{"gene":"NCK1","stoichiometry":0.2},{"gene":"NECAP1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/NSD2","total_profiled":1310},"omim":[{"mim_id":"619695","title":"RAUCH-STEINDL SYNDROME; RAUST","url":"https://www.omim.org/entry/619695"},{"mim_id":"613065","title":"LEUKEMIA, ACUTE LYMPHOBLASTIC; ALL","url":"https://www.omim.org/entry/613065"},{"mim_id":"607083","title":"NUCLEAR RECEPTOR-BINDING SET DOMAIN PROTEIN 3; NSD3","url":"https://www.omim.org/entry/607083"},{"mim_id":"606681","title":"NUCLEAR RECEPTOR-BINDING SET DOMAIN PROTEIN 1; NSD1","url":"https://www.omim.org/entry/606681"},{"mim_id":"602952","title":"NUCLEAR RECEPTOR-BINDING SET DOMAIN PROTEIN 2; NSD2","url":"https://www.omim.org/entry/602952"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nucleoli","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/NSD2"},"hgnc":{"alias_symbol":["MMSET","KMT3G"],"prev_symbol":["WHSC1"]},"alphafold":{"accession":"O96028","domains":[{"cath_id":"2.30.30.140","chopping":"225-362","consensus_level":"high","plddt":82.5688,"start":225,"end":362},{"cath_id":"3.30.40.10","chopping":"670-715","consensus_level":"medium","plddt":89.0715,"start":670,"end":715},{"cath_id":"2.170.270.10","chopping":"988-1178","consensus_level":"high","plddt":91.6335,"start":988,"end":1178}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O96028","model_url":"https://alphafold.ebi.ac.uk/files/AF-O96028-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O96028-F1-predicted_aligned_error_v6.png","plddt_mean":65.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NSD2","jax_strain_url":"https://www.jax.org/strain/search?query=NSD2"},"sequence":{"accession":"O96028","fasta_url":"https://rest.uniprot.org/uniprotkb/O96028.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O96028/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O96028"}},"corpus_meta":[{"pmid":"9787135","id":"PMC_9787135","title":"The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9787135","citation_count":442,"is_preprint":false},{"pmid":"21293379","id":"PMC_21293379","title":"MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21293379","citation_count":334,"is_preprint":false},{"pmid":"24076604","id":"PMC_24076604","title":"Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.","date":"2013","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24076604","citation_count":228,"is_preprint":false},{"pmid":"25188243","id":"PMC_25188243","title":"Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.","date":"2014","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25188243","citation_count":198,"is_preprint":false},{"pmid":"18156491","id":"PMC_18156491","title":"The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18156491","citation_count":160,"is_preprint":false},{"pmid":"15677557","id":"PMC_15677557","title":"Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15677557","citation_count":146,"is_preprint":false},{"pmid":"12433679","id":"PMC_12433679","title":"A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12433679","citation_count":141,"is_preprint":false},{"pmid":"22797064","id":"PMC_22797064","title":"The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22797064","citation_count":138,"is_preprint":false},{"pmid":"17942756","id":"PMC_17942756","title":"The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17942756","citation_count":133,"is_preprint":false},{"pmid":"23159737","id":"PMC_23159737","title":"Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer.","date":"2012","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/23159737","citation_count":124,"is_preprint":false},{"pmid":"21385930","id":"PMC_21385930","title":"The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors.","date":"2011","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/21385930","citation_count":120,"is_preprint":false},{"pmid":"28319045","id":"PMC_28319045","title":"AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/28319045","citation_count":108,"is_preprint":false},{"pmid":"19059936","id":"PMC_19059936","title":"MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.","date":"2008","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/19059936","citation_count":100,"is_preprint":false},{"pmid":"30666650","id":"PMC_30666650","title":"NSD2 circular RNA promotes metastasis of colorectal cancer by targeting miR-199b-5p-mediated DDR1 and JAG1 signalling.","date":"2019","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30666650","citation_count":82,"is_preprint":false},{"pmid":"18172012","id":"PMC_18172012","title":"Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18172012","citation_count":82,"is_preprint":false},{"pmid":"32378344","id":"PMC_32378344","title":"CircRNA WHSC1 targets the miR-646/NPM1 pathway to promote the development of endometrial cancer.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32378344","citation_count":79,"is_preprint":false},{"pmid":"27109101","id":"PMC_27109101","title":"MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27109101","citation_count":76,"is_preprint":false},{"pmid":"34555356","id":"PMC_34555356","title":"NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis.","date":"2021","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/34555356","citation_count":74,"is_preprint":false},{"pmid":"22972034","id":"PMC_22972034","title":"MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC.","date":"2012","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/22972034","citation_count":74,"is_preprint":false},{"pmid":"29728617","id":"PMC_29728617","title":"Depletion of Nsd2-mediated histone H3K36 methylation impairs adipose tissue development and function.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29728617","citation_count":73,"is_preprint":false},{"pmid":"31217297","id":"PMC_31217297","title":"PTEN Methylation by NSD2 Controls Cellular Sensitivity to DNA Damage.","date":"2019","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/31217297","citation_count":72,"is_preprint":false},{"pmid":"27164560","id":"PMC_27164560","title":"Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.","date":"2016","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/27164560","citation_count":72,"is_preprint":false},{"pmid":"34782742","id":"PMC_34782742","title":"A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization.","date":"2021","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/34782742","citation_count":71,"is_preprint":false},{"pmid":"31649247","id":"PMC_31649247","title":"NSD2 overexpression drives clustered chromatin and transcriptional changes in a subset of insulated domains.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31649247","citation_count":68,"is_preprint":false},{"pmid":"35230972","id":"PMC_35230972","title":"Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-γ-stimulated antitumor immunity.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/35230972","citation_count":67,"is_preprint":false},{"pmid":"23980095","id":"PMC_23980095","title":"NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23980095","citation_count":62,"is_preprint":false},{"pmid":"26272979","id":"PMC_26272979","title":"Unabridged Analysis of Human Histone H3 by Differential Top-Down Mass Spectrometry Reveals Hypermethylated Proteoforms from MMSET/NSD2 Overexpression.","date":"2015","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/26272979","citation_count":62,"is_preprint":false},{"pmid":"29945974","id":"PMC_29945974","title":"High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29945974","citation_count":60,"is_preprint":false},{"pmid":"16682010","id":"PMC_16682010","title":"Characterization of a novel WHSC1-associated SET domain protein with H3K4 and H3K27 methyltransferase activity.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16682010","citation_count":58,"is_preprint":false},{"pmid":"19481544","id":"PMC_19481544","title":"The histone methyltransferase, NSD2, enhances androgen receptor-mediated transcription.","date":"2009","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/19481544","citation_count":56,"is_preprint":false},{"pmid":"21527557","id":"PMC_21527557","title":"MMSET is highly expressed and associated with aggressiveness in neuroblastoma.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21527557","citation_count":54,"is_preprint":false},{"pmid":"33742125","id":"PMC_33742125","title":"NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33742125","citation_count":52,"is_preprint":false},{"pmid":"33522809","id":"PMC_33522809","title":"Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2.","date":"2021","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33522809","citation_count":52,"is_preprint":false},{"pmid":"11549311","id":"PMC_11549311","title":"WHSC1L1, on human chromosome 8p11.2, closely resembles WHSC1 and maps to a duplicated region shared with 4p16.3.","date":"2001","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/11549311","citation_count":50,"is_preprint":false},{"pmid":"30683853","id":"PMC_30683853","title":"Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30683853","citation_count":49,"is_preprint":false},{"pmid":"26787850","id":"PMC_26787850","title":"Transition state for the NSD2-catalyzed methylation of histone H3 lysine 36.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26787850","citation_count":46,"is_preprint":false},{"pmid":"35220680","id":"PMC_35220680","title":"Melatonin enhances osteoblastogenesis of senescent bone marrow stromal cells through NSD2-mediated chromatin remodelling.","date":"2022","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35220680","citation_count":46,"is_preprint":false},{"pmid":"30171259","id":"PMC_30171259","title":"An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30171259","citation_count":45,"is_preprint":false},{"pmid":"36976643","id":"PMC_36976643","title":"Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2.","date":"2023","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/36976643","citation_count":44,"is_preprint":false},{"pmid":"35532818","id":"PMC_35532818","title":"The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.","date":"2022","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/35532818","citation_count":43,"is_preprint":false},{"pmid":"38965384","id":"PMC_38965384","title":"Recruitment of FBXO22 for targeted degradation of NSD2.","date":"2024","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/38965384","citation_count":43,"is_preprint":false},{"pmid":"34671018","id":"PMC_34671018","title":"Identification of histone methyltransferase NSD2 as an important oncogenic gene in colorectal cancer.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34671018","citation_count":41,"is_preprint":false},{"pmid":"33941880","id":"PMC_33941880","title":"Loss-of-function and missense variants in NSD2 cause decreased methylation activity and are associated with a distinct developmental phenotype.","date":"2021","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33941880","citation_count":40,"is_preprint":false},{"pmid":"35984902","id":"PMC_35984902","title":"The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM.","date":"2023","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/35984902","citation_count":39,"is_preprint":false},{"pmid":"11152655","id":"PMC_11152655","title":"A unique mRNA initiated within a middle intron of WHSC1/MMSET encodes a DNA binding protein that suppresses human IL-5 transcription.","date":"2001","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11152655","citation_count":38,"is_preprint":false},{"pmid":"32573059","id":"PMC_32573059","title":"The NSD2/WHSC1/MMSET methyltransferase prevents cellular senescence-associated epigenomic remodeling.","date":"2020","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/32573059","citation_count":37,"is_preprint":false},{"pmid":"30345613","id":"PMC_30345613","title":"Developmental delay and failure to thrive associated with a loss-of-function variant in WHSC1 (NSD2).","date":"2018","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/30345613","citation_count":37,"is_preprint":false},{"pmid":"15198734","id":"PMC_15198734","title":"Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma.","date":"2004","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/15198734","citation_count":37,"is_preprint":false},{"pmid":"32764971","id":"PMC_32764971","title":"The Role of Methyltransferase NSD2 as a Potential Oncogene in Human Solid Tumors.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32764971","citation_count":37,"is_preprint":false},{"pmid":"30670815","id":"PMC_30670815","title":"Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling.","date":"2019","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/30670815","citation_count":36,"is_preprint":false},{"pmid":"35354439","id":"PMC_35354439","title":"METTL3 enhances NSD2 mRNA stability to reduce renal impairment and interstitial fibrosis in mice with diabetic nephropathy.","date":"2022","source":"BMC nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/35354439","citation_count":36,"is_preprint":false},{"pmid":"28512191","id":"PMC_28512191","title":"MiR-2392 suppresses metastasis and epithelial-mesenchymal transition by targeting MAML3 and WHSC1 in gastric cancer.","date":"2017","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/28512191","citation_count":33,"is_preprint":false},{"pmid":"23241889","id":"PMC_23241889","title":"The histone methyltransferase MMSET regulates class switch recombination.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23241889","citation_count":33,"is_preprint":false},{"pmid":"15483650","id":"PMC_15483650","title":"Evaluation of NSD2 and NSD3 in overgrowth syndromes.","date":"2005","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/15483650","citation_count":33,"is_preprint":false},{"pmid":"34417224","id":"PMC_34417224","title":"PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia.","date":"2021","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/34417224","citation_count":33,"is_preprint":false},{"pmid":"34782608","id":"PMC_34782608","title":"Structural basis of the regulation of the normal and oncogenic methylation of nucleosomal histone H3 Lys36 by NSD2.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34782608","citation_count":32,"is_preprint":false},{"pmid":"18182627","id":"PMC_18182627","title":"Identification of a novel proliferation-related protein, WHSC1 4a, in human gliomas.","date":"2008","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18182627","citation_count":32,"is_preprint":false},{"pmid":"23963300","id":"PMC_23963300","title":"Deletions involving genes WHSC1 and LETM1 may be necessary, but are not sufficient to cause Wolf-Hirschhorn Syndrome.","date":"2013","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/23963300","citation_count":31,"is_preprint":false},{"pmid":"23900284","id":"PMC_23900284","title":"Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma.","date":"2013","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/23900284","citation_count":27,"is_preprint":false},{"pmid":"35736136","id":"PMC_35736136","title":"H3K36me2 methyltransferase NSD2 orchestrates epigenetic reprogramming during spermatogenesis.","date":"2022","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/35736136","citation_count":26,"is_preprint":false},{"pmid":"26196464","id":"PMC_26196464","title":"MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.","date":"2015","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/26196464","citation_count":26,"is_preprint":false},{"pmid":"31636135","id":"PMC_31636135","title":"Histone methyltransferase Nsd2 is required for follicular helper T cell differentiation.","date":"2020","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31636135","citation_count":26,"is_preprint":false},{"pmid":"29892088","id":"PMC_29892088","title":"De novo truncating variants in WHSC1 recapitulate the Wolf-Hirschhorn (4p16.3 microdeletion) syndrome phenotype.","date":"2018","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29892088","citation_count":26,"is_preprint":false},{"pmid":"25188294","id":"PMC_25188294","title":"Histone H3 lysine 36 methyltransferase Whsc1 promotes the association of Runx2 and p300 in the activation of bone-related genes.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25188294","citation_count":26,"is_preprint":false},{"pmid":"37578463","id":"PMC_37578463","title":"Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2).","date":"2023","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37578463","citation_count":25,"is_preprint":false},{"pmid":"39251788","id":"PMC_39251788","title":"NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis.","date":"2024","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39251788","citation_count":24,"is_preprint":false},{"pmid":"25093175","id":"PMC_25093175","title":"MMSET: role and therapeutic opportunities in multiple myeloma.","date":"2014","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/25093175","citation_count":24,"is_preprint":false},{"pmid":"27404348","id":"PMC_27404348","title":"Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells.","date":"2016","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/27404348","citation_count":24,"is_preprint":false},{"pmid":"29233865","id":"PMC_29233865","title":"DICER- and MMSET-catalyzed H4K20me2 recruits the nucleotide excision repair factor XPA to DNA damage sites.","date":"2017","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29233865","citation_count":23,"is_preprint":false},{"pmid":"22886632","id":"PMC_22886632","title":"Overexpression of MMSET in endometrial cancer: a clinicopathologic study.","date":"2012","source":"Journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22886632","citation_count":23,"is_preprint":false},{"pmid":"31171569","id":"PMC_31171569","title":"De novo loss-of-function variants in NSD2 (WHSC1) associate with a subset of Wolf-Hirschhorn syndrome.","date":"2019","source":"Cold Spring Harbor molecular case studies","url":"https://pubmed.ncbi.nlm.nih.gov/31171569","citation_count":23,"is_preprint":false},{"pmid":"35704853","id":"PMC_35704853","title":"Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors.","date":"2022","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35704853","citation_count":22,"is_preprint":false},{"pmid":"32001260","id":"PMC_32001260","title":"S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis.","date":"2020","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/32001260","citation_count":22,"is_preprint":false},{"pmid":"16197452","id":"PMC_16197452","title":"Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4;14) in multiple myeloma.","date":"2005","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/16197452","citation_count":22,"is_preprint":false},{"pmid":"31235934","id":"PMC_31235934","title":"Whsc1 links pluripotency exit with mesendoderm specification.","date":"2019","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/31235934","citation_count":22,"is_preprint":false},{"pmid":"36918219","id":"PMC_36918219","title":"All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma.","date":"2023","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36918219","citation_count":21,"is_preprint":false},{"pmid":"33469000","id":"PMC_33469000","title":"Histone methyltransferase WHSC1 inhibits colorectal cancer cell apoptosis via targeting anti-apoptotic BCL2.","date":"2021","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/33469000","citation_count":21,"is_preprint":false},{"pmid":"33420361","id":"PMC_33420361","title":"Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33420361","citation_count":21,"is_preprint":false},{"pmid":"36863225","id":"PMC_36863225","title":"Recent advances in nuclear receptor-binding SET domain 2 (NSD2) inhibitors: An update and perspectives.","date":"2023","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36863225","citation_count":20,"is_preprint":false},{"pmid":"33602783","id":"PMC_33602783","title":"SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic PTP4A3 through Chromatin Remodeling in t(4;14) Multiple Myeloma.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33602783","citation_count":20,"is_preprint":false},{"pmid":"34147909","id":"PMC_34147909","title":"5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.","date":"2021","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34147909","citation_count":20,"is_preprint":false},{"pmid":"34551195","id":"PMC_34551195","title":"Circular RNA WHSC1 exerts oncogenic properties by regulating miR-7/TAB2 in lung cancer.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34551195","citation_count":19,"is_preprint":false},{"pmid":"36642961","id":"PMC_36642961","title":"Structural Modification and Pharmacological Evaluation of Substituted Quinoline-5,8-diones as Potent NSD2 Inhibitors.","date":"2023","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36642961","citation_count":19,"is_preprint":false},{"pmid":"32472076","id":"PMC_32472076","title":"H3K36 dimethylation by MMSET promotes classical non-homologous end-joining at unprotected telomeres.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32472076","citation_count":19,"is_preprint":false},{"pmid":"31040165","id":"PMC_31040165","title":"NSD2 silencing alleviates pulmonary arterial hypertension by inhibiting trehalose metabolism and autophagy.","date":"2019","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/31040165","citation_count":19,"is_preprint":false},{"pmid":"32801739","id":"PMC_32801739","title":"WHSC1 Promotes Cell Proliferation, Migration, and Invasion in Hepatocellular Carcinoma by Activating mTORC1 Signaling.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32801739","citation_count":18,"is_preprint":false},{"pmid":"25677622","id":"PMC_25677622","title":"Retinoic acid inhibits histone methyltransferase Whsc1 during palatogenesis.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25677622","citation_count":18,"is_preprint":false},{"pmid":"33552680","id":"PMC_33552680","title":"Long non-coding RNAs MACC1-AS1 and FOXD2-AS1 mediate NSD2-induced cisplatin resistance in esophageal squamous cell carcinoma.","date":"2020","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/33552680","citation_count":18,"is_preprint":false},{"pmid":"30470837","id":"PMC_30470837","title":"MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells.","date":"2018","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/30470837","citation_count":17,"is_preprint":false},{"pmid":"31248990","id":"PMC_31248990","title":"Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31248990","citation_count":17,"is_preprint":false},{"pmid":"38687638","id":"PMC_38687638","title":"Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38687638","citation_count":17,"is_preprint":false},{"pmid":"26771714","id":"PMC_26771714","title":"MMSET is dynamically regulated during cell-cycle progression and promotes normal DNA replication.","date":"2016","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/26771714","citation_count":17,"is_preprint":false},{"pmid":"32314642","id":"PMC_32314642","title":"WHSC1 promotes wnt/β-catenin signaling in a FoxM1-dependent manner facilitating proliferation, invasion and epithelial-mesenchymal transition in breast cancer.","date":"2020","source":"Journal of receptor and signal transduction research","url":"https://pubmed.ncbi.nlm.nih.gov/32314642","citation_count":16,"is_preprint":false},{"pmid":"31692936","id":"PMC_31692936","title":"Knockdown of NSD2 Suppresses Renal Cell Carcinoma Metastasis by Inhibiting Epithelial-Mesenchymal Transition.","date":"2019","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31692936","citation_count":16,"is_preprint":false},{"pmid":"35322173","id":"PMC_35322173","title":"Histone methyltransferase Nsd2 ensures maternal-fetal immune tolerance by promoting regulatory T-cell recruitment.","date":"2022","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35322173","citation_count":16,"is_preprint":false},{"pmid":"32021450","id":"PMC_32021450","title":"NSD2 Promotes Renal Cancer Progression Through Stimulating Akt/Erk Signaling.","date":"2020","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/32021450","citation_count":16,"is_preprint":false},{"pmid":"16115125","id":"PMC_16115125","title":"Identification of ID-1 as a potential target gene of MMSET in multiple myeloma.","date":"2005","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/16115125","citation_count":15,"is_preprint":false},{"pmid":"39390582","id":"PMC_39390582","title":"Systematic perturbations of SETD2, NSD1, NSD2, NSD3, and ASH1L reveal their distinct contributions to H3K36 methylation.","date":"2024","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/39390582","citation_count":14,"is_preprint":false},{"pmid":"40097917","id":"PMC_40097917","title":"H3K36me2 methyltransferase NSD2/WHSC1 promotes triple-negative breast cancer metastasis via activation of ULK1-dependent autophagy.","date":"2025","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/40097917","citation_count":14,"is_preprint":false},{"pmid":"37463241","id":"PMC_37463241","title":"Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma.","date":"2023","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/37463241","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48643,"output_tokens":10659,"usd":0.152907},"stage2":{"model":"claude-opus-4-6","input_tokens":14638,"output_tokens":4597,"usd":0.282172},"total_usd":0.435079,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"MMSET (NSD2) was identified as a novel gene disrupted by the t(4;14)(p16.3;q32.3) translocation in multiple myeloma. The long form (1365 aa) contains HMG box, hath region, 4 PHD fingers, and a SET domain, while a short form (647 aa) contains the HMG box and hath region. The translocation results in IgH/MMSET hybrid transcripts and overexpression from endogenous promoters.\",\n      \"method\": \"Molecular cloning, RT-PCR, domain analysis, translocation breakpoint mapping\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — foundational discovery paper, highly cited, multiple molecular methods\",\n      \"pmids\": [\"9787135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"A mRNA initiated within the middle intron of WHSC1/MMSET encodes RE-IIBP, a protein containing a SET domain and two PHD-type zinc fingers that specifically binds the IL-5 response element RE-II and represses IL-5 transcription when expressed in activated T cells.\",\n      \"method\": \"Expression cloning, EMSA, 5'-RACE, transfection reporter assays, luciferase reporter\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional assays but single lab\",\n      \"pmids\": [\"11152655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MMSET I isoform represses transcription of a chromatin-embedded reporter gene in a dose-dependent manner and specifically recruits HDAC1 and mSin3b (but not HDAC2 or HDAC4) as shown by co-immunoprecipitation; HDAC inhibitor trichostatin A reduces repression activity.\",\n      \"method\": \"Co-immunoprecipitation, transcriptional reporter assays, HDAC inhibitor treatment\",\n      \"journal\": \"British journal of haematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP plus functional reporter assay, single lab\",\n      \"pmids\": [\"16197452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"All transcripts from the WHSC1/MMSET/NSD2 locus are uniformly overexpressed in t(4;14)+ myeloma patients. GFP-tagged MMSET I and II localize to the nucleus (not nucleoli), while MB4-2 and MB4-3 breakpoint variant proteins concentrate in nucleoli. FRAP kinetic studies show breakpoint variants are functionally distinct from wild-type proteins. Exon 4a/MMSET III contains a domain that prevents nucleolar localization.\",\n      \"method\": \"Quantitative RT-PCR, GFP-tagging, fluorescence live-cell imaging, FRAP\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct live-cell localization with functional consequence, single lab\",\n      \"pmids\": [\"15677557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MMSET possesses histone methyltransferase activity for H3K4 and H4K20 in vitro; in cells, MMSET modifies only H4K20. MMSET fused to Gal4 DNA-binding domain represses transcription of a chromatin-embedded reporter, associated with increased H4K20 methylation and loss of histone acetylation. MMSET forms a complex with HDAC1, HDAC2, mSin3a, and the histone demethylase LSD1.\",\n      \"method\": \"In vitro methyltransferase assay, Gal4-reporter transcription assay, co-immunoprecipitation\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro enzymatic assay combined with co-IP complex identification and functional reporter, replicated across multiple methods\",\n      \"pmids\": [\"18156491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MMSET knockdown by RNAi and selective disruption of the translocated MMSET allele by gene targeting dramatically reduced colony formation in methylcellulose, caused cell-cycle arrest of adherent MM cells, reduced adhesion to extracellular matrix, and reduced tumor formation in xenografts.\",\n      \"method\": \"RNAi knockdown, gene targeting/knockout, colony formation assay, xenograft mouse model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal loss-of-function approaches with defined cellular phenotypes\",\n      \"pmids\": [\"17942756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RE-IIBP (an MMSET isoform) has histone H3K27 methyltransferase activity; SET domain residues C483 and R477 are critical for this activity. RE-IIBP represses transcription via HDAC recruitment mediated by H3K27 methylation, demonstrated at the IL-5 promoter by ChIP showing increased H3K27me, HDAC recruitment, and H3 hypoacetylation.\",\n      \"method\": \"In vitro HMTase assay, point mutant analysis, ChIP, luciferase reporter\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assay with active-site mutagenesis plus ChIP and reporter assay\",\n      \"pmids\": [\"18172012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"NSD2 specifically interacts with the DNA-binding domain of androgen receptor (AR) via its HMG domain. Nuclear translocation of both NSD2 and AR is enhanced in the presence of ligand. NSD2 overexpression, but not the SET-domain mutant (ΔSET, HMT-defective), enhances PSA mRNA levels. ChIP showed NSD2 is recruited to the PSA gene enhancer by AR in an agonist-dependent manner.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, qRT-PCR, domain deletion mutant\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal functional validation with domain mutant and ChIP, single lab\",\n      \"pmids\": [\"19481544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"MMSET (NSD2) is recruited to DNA double-strand breaks (DSBs) via interaction between the MDC1 BRCT domain and phosphorylated Ser102 of MMSET, dependent on the γH2AX-MDC1 pathway. Once recruited, MMSET mediates local H4K20 dimethylation at DSBs, which facilitates 53BP1 accumulation at damage sites.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, shRNA knockdown, laser-induced DSBs, immunofluorescence\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, direct interaction mapping, published in Nature, highly cited\",\n      \"pmids\": [\"21293379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MMSET knockdown in prostate cancer cells decreased H3K36me2 and H3K27me3, reduced cell migration and invasion, and blocked EMT. MMSET overexpression in non-transformed RWPE-1 cells promoted invasion and EMT. ChIP showed MMSET binds the TWIST1 locus and increases H3K36me2, directly activating TWIST1 expression, which is the critical mediator of MMSET-driven invasion.\",\n      \"method\": \"ChIP, shRNA knockdown, overexpression, invasion/migration assays, EMT marker analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP directly links MMSET to target gene, isogenic gain/loss models, mechanistic rescue experiment\",\n      \"pmids\": [\"22797064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"EZH2 functions upstream of MMSET in a coordinated HMTase axis regulated by a microRNA network. EZH2-mediated H3K27me3 and MMSET-mediated H3K36me2 are coordinately regulated, and the oncogenic functions of EZH2 require MMSET activity.\",\n      \"method\": \"Genetic knockdown epistasis, microRNA overexpression/inhibition, ChIP\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis and ChIP with multiple methods, single lab\",\n      \"pmids\": [\"23159737\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MMSET promotes proliferation of multiple myeloma cells by stimulating c-MYC expression at the post-transcriptional level. MMSET represses miR-126* by binding to its promoter along with the KAP1 corepressor and HDACs, leading to heterochromatic modifications (increased H3K9me3, decreased H3 acetylation). miR-126* targets the 3'-UTR of c-MYC mRNA to inhibit its translation.\",\n      \"method\": \"miRNA profiling, ChIP, luciferase 3'-UTR reporter assay, miRNA overexpression\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus 3'-UTR reporter validates mechanism, single lab\",\n      \"pmids\": [\"22972034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MMSET plays an important role in class switch recombination (CSR) through its histone methyltransferase activity. MMSET knockdown impaired 53BP1 recruitment to Igh switch regions and decreased germline transcription of switch regions, resulting in defective CSR without affecting cell growth or viability.\",\n      \"method\": \"shRNA knockdown, CSR assay, 53BP1 recruitment immunofluorescence, germline transcription RT-PCR\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined cellular phenotype (CSR) with mechanistic link to 53BP1, single lab\",\n      \"pmids\": [\"23241889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NSD2 methyltransferase activity is crucial for clonogenicity, adherence, and proliferation of multiple myeloma cells on bone marrow stroma. The PHD domains of NSD2 are required for its cellular activity and recruit NSD2 to oncogenic target gene loci to drive their transcriptional activation.\",\n      \"method\": \"PHD domain mutants, ChIP, colony formation, proliferation assays, xenograft\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — domain mutagenesis combined with ChIP and functional assays\",\n      \"pmids\": [\"23980095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NSD2 p.E1099K is an activating mutation that increases H3K36 dimethylation and promotes transformation; NSD2 knockdown selectively inhibits proliferation of NSD2-mutant ALL cell lines and impairs in vivo growth of NSD2-mutant ALL xenografts. Global histone profiling by mass spectrometry identified the distinct H3K36me2 signature of NSD2 hyperactivation.\",\n      \"method\": \"High-information-content mass spectrometry histone profiling, ectopic expression, shRNA knockdown, xenograft\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — MS-based chromatin profiling plus gain/loss-of-function in vitro and in vivo, replicated in >1000 cancer genomes\",\n      \"pmids\": [\"24076604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MMSET overexpression causes a global increase in H3K36me2 and a global reduction of H3K27me3. Despite net decrease in H3K27me3, specific loci show enhanced EZH2 recruitment and become hypermethylated on H3K27. PHD domains of MMSET mediate its chromatin recruitment and are required for these epigenetic changes.\",\n      \"method\": \"ChIP-seq, shRNA inducible knockdown, PHD domain mutants, xenograft tumor regression\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genome-wide ChIP-seq with domain mutants and in vivo validation\",\n      \"pmids\": [\"25188243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Whsc1 promotes the association of Runx2 and p300 to activate bone-related genes (Osteopontin, Col1a1). Whsc1 suppresses overactivation of these genes via H3K36 trimethylation. Whsc1-/- embryos exhibit defects in ossification, and Whsc1 knockdown in pre-osteoblasts perturbs histone modification patterns at bone-related gene loci.\",\n      \"method\": \"Co-immunoprecipitation (Runx2/p300 association), ChIP, Whsc1 knockout mouse, siRNA knockdown, bone differentiation assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP plus ChIP plus KO model with skeletal phenotype\",\n      \"pmids\": [\"25188294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NSD2 catalyzes H3K36 dimethylation via an SN2 mechanism where methyl transfer is the first irreversible chemical step. The transition state is a late, asymmetric nucleophilic displacement with bond separation from the leaving group at 2.53 Å and bond making to the attacking nucleophile at 2.10 Å. NSD2 preferentially catalyzes H3K36 dimethylation over monomethylation.\",\n      \"method\": \"Kinetic isotope effect measurements, quantum chemical/computational modeling, in vitro enzymatic assay with nucleosome substrate\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — rigorous in vitro mechanistic chemistry with KIE measurements and quantum modeling\",\n      \"pmids\": [\"26787850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MMSET is required for efficient non-homologous end joining (NHEJ) and homologous recombination (HR). Loss of MMSET leads to loss of expression of several DNA repair proteins and decreased recruitment of DNA repair proteins to DSB sites. MMSET-high cells repair DNA damage at enhanced rate compared to MMSET-low isogenic cells.\",\n      \"method\": \"NHEJ/HR reporter assays, immunofluorescence of DNA repair factor recruitment, isogenic MM cell line pairs, xenograft\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — isogenic cell lines, multiple repair assays, defined molecular phenotype\",\n      \"pmids\": [\"27109101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MMSET is degraded during S phase in a CRL4(Cdt2)- and proteasome-dependent manner. MMSET depletion causes defects in DNA replication and decreased association of pre-replication complex (pre-RC) factors with chromatin, indicating a role for MMSET in normal DNA replication.\",\n      \"method\": \"Cell synchronization, co-immunoprecipitation, chromatin fractionation, DNA fiber assay\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct mechanistic link between protein stability regulation and DNA replication phenotype, single lab\",\n      \"pmids\": [\"26771714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NSD2 (methyltransferase-active) is recruited to promoters of glucose metabolic enzyme genes (HK2, G6PD, TIGAR) and methylates H3K36me2 at these loci, coordinately upregulating their expression to drive pentose phosphate pathway activity and endocrine resistance in breast cancer. Methylase-defective NSD2 mutant cannot drive resistance.\",\n      \"method\": \"ChIP, gene expression profiling, methylase-dead mutant, xenograft, PPP activity assay\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP with catalytic mutant control demonstrates direct epigenetic regulation of metabolic genes\",\n      \"pmids\": [\"27164560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"AKT phosphorylates WHSC1 at S172 upon PTEN loss, preventing its degradation by CRL4Cdt2 E3 ligase. Increased WHSC1 transcriptionally upregulates RICTOR (mTORC2 component) to further enhance AKT activity, forming a feedback loop. WHSC1 also positively regulates Rac1 transcription to increase tumor cell motility.\",\n      \"method\": \"In vivo mouse PCa model (PTEN-null + WHSC1 overexpression), genetic ablation, phosphorylation mapping, co-immunoprecipitation, ChIP\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo genetic model combined with biochemical phosphorylation mapping and multiple orthogonal methods\",\n      \"pmids\": [\"28319045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DICER mediates the recruitment of MMSET to UV-induced DNA damage sites. MMSET is required for efficient nucleotide excision repair (NER) by catalyzing H4K20me2 at DNA damage sites, which facilitates recruitment of the NER factor XPA.\",\n      \"method\": \"Immunofluorescence at UV damage sites, MMSET knockdown, ChIP, XPA recruitment assay\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiments with functional NER assay and mechanistic link to XPA\",\n      \"pmids\": [\"29233865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The NSD2 E1099K mutation alters enzyme/substrate binding and enhances the rate of H3K36 methylation in vitro. E1099K cells exhibit increased H3K36me2, reduced H3K27me3 (particularly on H3.1-containing nucleosomes), reduced apoptosis, and enhanced proliferation, clonogenicity, adhesion, migration, and brain invasion in xenografts.\",\n      \"method\": \"Gene-edited isogenic cell lines, in vitro enzymatic assay, transcriptional profiling, xenograft\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — gene editing plus in vitro kinetics plus comprehensive phenotyping\",\n      \"pmids\": [\"30171259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DNA DSBs promote NSD2-mediated dimethylation of PTEN at K349; this methylation is recognized by the tudor domain of 53BP1 to recruit PTEN to DNA-damage sites, governing efficient DSB repair partly through dephosphorylation of γH2AX. ATM-dependent phosphorylation of T/S398-PTEN promotes PTEN interaction with MDC1 upstream of NSD2 activity.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry methylation mapping, site-directed mutagenesis, in vitro methylation assay, xenograft\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical methylation mapping with mutagenesis, in vitro assay, and in vivo validation\",\n      \"pmids\": [\"31217297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NSD2 promotes tumor angiogenesis by methylating STAT3 at K163; mass spectrometry and site-directed mutagenesis confirmed this methylation site. K163R STAT3 mutant shows attenuated activation and angiogenic function. NSD2 promotes STAT3 activation through a methylation-phosphorylation regulation pattern, driving VEGFA expression.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, site-directed mutagenesis (K163R), in vitro methylation assay, angiogenesis assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — MS-confirmed methylation site with mutagenesis validation, single lab\",\n      \"pmids\": [\"33742125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NSD2 overexpression drives chromatin and transcriptional changes linked to oncogene activation within insulated topological domains. NSD2-driven expansion of H3K36me2 leads to alterations in H3K27ac and CTCF binding within H3K36me2-enriched chromatin, and differentially expressed genes are significantly enriched within the same insulated domain as altered H3K27ac and CTCF peaks.\",\n      \"method\": \"ChIP-seq, Hi-C/3D genome organization, isogenic cell lines (high vs. low NSD2), logistic regression modeling\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide multi-omics in isogenic lines, single lab\",\n      \"pmids\": [\"31649247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PARP1 directly interacts with NSD2 (identified by BioID proximity labeling and MS). Upon oxidative stress, PARP1 PARylates NSD2, which significantly reduces NSD2 histone methyltransferase activity in vitro and inhibits NSD2 binding to nucleosomes and its recruitment to NSD2-regulated gene loci.\",\n      \"method\": \"BioID proximity labeling, mass spectrometry, in vitro methyltransferase assay, nucleosome binding assay, ChIP\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — interactome discovery plus in vitro enzymatic assay validation plus ChIP, multiple orthogonal methods\",\n      \"pmids\": [\"31248990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Whsc1 (NSD2) is required for follicular helper T (Tfh) cell differentiation. CD28 signaling induces Nsd2 expression, which is required for Bcl6 expression as early as the first cell division after T cell activation. Nsd2 deficiency impairs Tfh generation, germinal center response, and virus clearance. Ectopic Bcl6 expression rescues the Tfh defect of Nsd2 KO cells.\",\n      \"method\": \"Conditional knockout, Bcl6 rescue experiment, germinal center assays, flow cytometry\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with genetic rescue establishing epistatic relationship\",\n      \"pmids\": [\"31636135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Whsc1 has a dual role in pluripotency exit and germ layer specification in mouse embryonic stem cells. Whsc1 binds to enhancers of mesendodermal regulators (Gata4, Brachyury, Gata6, Foxa2) together with Brd4 to activate their expression. Notably, these functions are independent of Whsc1 methyltransferase activity.\",\n      \"method\": \"Conditional depletion, ChIP, co-immunoprecipitation with Brd4, directed differentiation assays, methyltransferase-dead mutant\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and catalytic mutant establish non-enzymatic function, single lab\",\n      \"pmids\": [\"31235934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NSD2 knockdown in primary human fibroblasts induces cellular senescence via RB-mediated downregulation of cell cycle-related genes. NSD2 is enriched at gene bodies of actively transcribed genes including cell cycle-related genes, and NSD2 loss decreases H3K36me3 at these loci. Serum stimulation upregulates NSD2 and induces cell cycle gene expression.\",\n      \"method\": \"RNAi screen, ChIP, transcriptome analysis, senescence assays (SA-β-gal, mitochondrial mass)\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP links NSD2 occupancy to H3K36me3 at target loci with functional senescence phenotype\",\n      \"pmids\": [\"32573059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MMSET promotes H3K36me2 at deprotected telomeres through its SET-domain catalytic activity, and this promotes classical (Ligase4-dependent) NHEJ at deprotected telomeres. MMSET-dependent H3K36me2 levels directly correlate with NHEJ efficiency; MMSET depletion does not affect upstream DDR recognition but acts downstream at the repair step.\",\n      \"method\": \"Methyltransferase screen, MMSET knockdown, telomere dysfunction assay, ChIP, Ligase4-dependent NHEJ assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct correlation between enzymatic activity and NHEJ in defined assay system\",\n      \"pmids\": [\"32472076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Cryo-EM structure of NSD2 bound to the nucleosome reveals that nucleosomal DNA is partially unwrapped to facilitate NSD2 access to H3K36. NSD2 interacts with DNA, H2A, and H3. The autoinhibitory loop changes conformation upon nucleosome binding to accommodate H3 in the substrate-binding cleft. E1099K and T1150A oncogenic mutations increase catalytic turnover by destabilizing interactions that keep the autoinhibitory loop closed.\",\n      \"method\": \"Cryo-electron microscopy structure determination, kinetic analysis, molecular dynamics simulation\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution cryo-EM structure with functional kinetic validation and MD simulation of oncogenic mutations\",\n      \"pmids\": [\"34782608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NSD2 PWWP1 domain occupies a canonical H3K36me2-binding pocket. A chemical probe (UNC6934) targeting PWWP1 antagonizes its interaction with nucleosomal H3K36me2 and induces accumulation of endogenous NSD2 in the nucleolus, phenocopying localization defects of NSD2 isoforms lacking PWWP1 (as occur in t(4;14) MM). Mutations in other NSD2 chromatin reader domains also increase NSD2 nucleolar localization.\",\n      \"method\": \"Chemical probe (UNC6934), co-crystal structure of PWWP1/probe, cellular NSD2 localization by imaging, nucleosome-binding assays\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus chemical probe with functional cellular localization consequence\",\n      \"pmids\": [\"34782742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NSD2 E1099K mutation drives glucocorticoid resistance in pediatric ALL by causing H3K27me3 accumulation at the NR3C1 (glucocorticoid receptor) promoter, repressing GR expression and blocking GR autoactivation. PRC2 inhibitors remove this H3K27me3, restore NR3C1 expression, and reverse glucocorticoid resistance in vitro and in vivo.\",\n      \"method\": \"High-throughput drug screening, CRISPR correction of E1099K, ChIP-seq, PRC2 inhibitor treatment, PDX model\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR isogenic correction, genome-wide ChIP-seq, PDX validation, clear mechanistic pathway\",\n      \"pmids\": [\"34417224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NSD2 interacts with SMARCA2 (SWI/SNF ATPase subunit) in a non-canonical, SWI/SNF complex-independent manner. The NSD2-SMARCA2 complex is mapped to the PTP4A3 promoter by ChIP, leading to focal H3K36me2 increase and transcriptional activation of PTP4A3, which maintains MYC expression. BET inhibitor PFI-3 displaces NSD2 from the PTP4A3 promoter.\",\n      \"method\": \"SILAC-based mass spectrometry interactome, co-immunoprecipitation, ChIP, RNA-seq\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — MS-based interactome validated by co-IP and ChIP, single lab\",\n      \"pmids\": [\"33602783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NSD2 via H3K36me2 catalysis cooperates with oncogenic KRAS signaling to drive lung adenocarcinoma (LUAD) pathogenesis in vivo. NSD2E1099K expression accelerates malignant tumor progression in KRAS-driven LUAD mouse models. Pathologic H3K36me2 generation amplifies transcriptional output of KRAS and complementary oncogenic gene expression programs.\",\n      \"method\": \"In vivo LUAD mouse model, CRISPRi-based knockdown, PDX model, MEK inhibitor combination, ChIP-seq\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo genetic model with CRISPRi, PDX, and ChIP-seq, rigorous epistasis with KRAS pathway\",\n      \"pmids\": [\"34555356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"WHSC1 loss impairs IFN-γ-stimulated antitumor immunity by transcriptionally downregulating MHC-I machinery without affecting PD-L1. WHSC1 directly interacts with NLRC5 to promote MHC-I gene expression. IFN-γ/STAT1 signaling stimulates WHSC1 expression, which in turn promotes NLRC5-dependent antigen presentation.\",\n      \"method\": \"Co-immunoprecipitation (WHSC1-NLRC5), shRNA knockdown, CRC organoids, xenografts, Apcmin/+ mouse model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct interaction identified by co-IP, multiple in vivo models, defined immune phenotype\",\n      \"pmids\": [\"35230972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Loss-of-function and missense NSD2 variants cause reduced H3K36 methyltransferase activity in vitro; missense variants fail to reconstitute H3K36me2 in NSD2 knockout cells. Structural modeling indicates interference with NSD2 folding and function for missense variants in known structural domains.\",\n      \"method\": \"In vitro methylation assay, NSD2 KO cell complementation, in silico structural modeling\",\n      \"journal\": \"Genetics in medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro enzyme assay with KO complementation, multiple variants tested\",\n      \"pmids\": [\"33941880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Nsd2 (but not Nsd1 or Setd2) is required for adipogenesis; depletion of Nsd2 in preadipocytes phenocopies H3.3K36M effects by increasing H3K27me3 to prevent induction of C/EBPα and PPARγ target genes. In differentiated adipocytes, Nsd2 loss does not affect tissue weight but leads to BAT whitening and insulin resistance in WAT.\",\n      \"method\": \"shRNA knockdown of Nsd2/Nsd1/Setd2 (selective comparison), H3.3K36M expression, adipogenesis assays, in vivo mouse models, ChIP\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — selective comparison among paralogues establishes specificity, in vitro and in vivo validation\",\n      \"pmids\": [\"29728617\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Nsd2 deficiency in mouse spermatogenic cells reduces H3K36me2 and H3K36me3 genome-wide, with H3K36me2 occupancy positively correlating with germline gene expression. Nsd2 loss leads to H4K16ac elevation through interaction with PSMA8 (which regulates acetylated histone degradation), impairs EP300-induced H4K5/8ac and BRDT-mediated histone eviction, causing histone retention in spermatozoa.\",\n      \"method\": \"Conditional knockout, ChIP-seq, co-immunoprecipitation (NSD2-PSMA8), spermatogenesis assays, fertility phenotype\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with ChIP-seq and co-IP defining mechanistic cascade, single lab\",\n      \"pmids\": [\"35736136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Nsd2 upregulates CXCR4 expression via H3K36me2 modification to promote regulatory T cell recruitment to the maternal-fetal interface. Nsd2 conditional KO in Tregs specifically reduces Treg levels at the decidua and causes fetal loss without affecting systemic Treg development or function.\",\n      \"method\": \"Conditional knockout, ChIP (H3K36me2 at CXCR4 locus), Treg recruitment assay, pregnancy model\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with ChIP and defined cellular recruitment phenotype, single lab\",\n      \"pmids\": [\"35322173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in prostate cancer. Tumor-specific AR enhancers critically rely on NSD2's H3K36 dimethyltransferase activity. NSD2 inactivation disrupts over 65% of AR cistrome; NSD2-dependent AR sites harbor a chimeric FOXA1:AR half-motif exclusive to tumor-specific enhancers.\",\n      \"method\": \"ChIP-seq (AR, NSD2, H3K36me2), NSD2 inactivation, AR cistrome analysis, PROTAC degrader, patient specimens\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide ChIP-seq with genetic inactivation and PROTAC degrader, validated in patient specimens\",\n      \"pmids\": [\"39251788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NSD2 is selectively degraded by a PROTAC (UNC8153) through a novel mechanism via a simple warhead, and separately by UNC8732 through FBXO22 recruitment (FBXO22's C326 is engaged by an aldehyde metabolite). Both degraders reduce H3K36me2, suppress MM cell adhesion and proliferation, and cause apoptosis and drug resistance reversal in NSD2-mutant ALL cells.\",\n      \"method\": \"PROTAC degradation assay, proteasome/cereblon/FBXO22 dependence assays, H3K36me2 western blot, anti-proliferative assays\",\n      \"journal\": \"Journal of the American Chemical Society / Nature chemical biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic E3 ligase identification with defined biochemical readout\",\n      \"pmids\": [\"36976643\", \"38965384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Systematic perturbation of H3K36 methyltransferases established that NSD2 (along with NSD1) is responsible for deposition of broad intergenic H3K36me2 domains, while NSD3 deposits H3K36me2 peaks on active promoters and enhancers. A hierarchy of K36MT activities was determined: NSD1 > NSD2 > NSD3 > ASH1L for intergenic H3K36me1/2 deposition.\",\n      \"method\": \"CRISPR knockout of individual K36MTs, ChIP-seq (H3K36me1/2/3), RNA-seq, mouse mesenchymal stem cells\",\n      \"journal\": \"Genome biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic parallel KO comparisons with genome-wide ChIP-seq establishing functional hierarchy\",\n      \"pmids\": [\"39390582\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NSD2 (MMSET/WHSC1) is a histone H3K36 di-methyltransferase whose SET domain catalyzes an SN2 methyl-transfer reaction on nucleosomes via an autoinhibitory loop that opens upon nucleosome engagement; it is recruited to chromatin through its PWWP1 domain (which reads H3K36me2) and PHD domains, and its overexpression or activating mutations (e.g., E1099K, T1150A) drive global H3K36me2 expansion with reciprocal H3K27me3 reduction, reprogramming gene expression to promote oncogenesis, while in the DNA damage response it is recruited to DSBs via γH2AX-MDC1 interaction to locally deposit H4K20me2 (facilitating 53BP1 recruitment) and H3K36me2 (promoting NHEJ/HR), and it also non-histone substrates including PTEN-K349 and STAT3-K163, interacts with complexes including HDAC1/HDAC2/LSD1/mSin3a, SMARCA2, and NLRC5, and is regulated post-translationally by AKT-mediated phosphorylation at S172 (blocking CRL4Cdt2-dependent degradation) and PARP1-mediated PARylation (reducing its methyltransferase activity and chromatin binding).\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"NSD2 (MMSET/WHSC1) is a histone H3K36 dimethyltransferase that catalyzes broad intergenic H3K36me2 deposition on nucleosomal substrates via an SN2 methyl-transfer mechanism, with an autoinhibitory loop that opens upon nucleosome engagement to grant access to H3K36; its overexpression or activating mutations (E1099K, T1150A) drive global H3K36me2 expansion with reciprocal H3K27me3 reduction, reprogramming enhancer landscapes, CTCF binding, and gene expression to promote oncogenesis in multiple myeloma, ALL, prostate cancer, and lung adenocarcinoma [PMID:34782608, PMID:24076604, PMID:25188243, PMID:31649247, PMID:34555356]. Beyond histone methylation, NSD2 methylates non-histone substrates including PTEN-K349 (facilitating 53BP1-mediated DSB repair) and STAT3-K163 (promoting angiogenesis), and is recruited to DNA damage sites via γH2AX–MDC1 interaction to deposit H4K20me2 and H3K36me2 that promote NHEJ, HR, and nucleotide excision repair [PMID:21293379, PMID:31217297, PMID:33742125, PMID:27109101, PMID:29233865]. NSD2 also functions in a catalytic-activity-independent manner as a scaffold at enhancers with BRD4 during germ-layer specification, interacts with NLRC5 to drive MHC-I antigen presentation, and serves as a requisite subunit of the AR/FOXA1 neo-enhanceosome at tumor-specific prostate cancer enhancers [PMID:31235934, PMID:35230972, PMID:39251788]. NSD2 protein stability is regulated by CRL4Cdt2-dependent S-phase degradation counteracted by AKT-mediated phosphorylation at S172, and its enzymatic activity is inhibited by PARP1-mediated PARylation [PMID:26771714, PMID:28319045, PMID:31248990].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Identification of NSD2 as the gene disrupted by the t(4;14) translocation in multiple myeloma established it as a candidate oncogene and revealed its multi-domain architecture (HMG, PHD fingers, SET domain).\",\n      \"evidence\": \"Molecular cloning and translocation breakpoint mapping in MM patient samples\",\n      \"pmids\": [\"9787135\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enzymatic activity of the SET domain was unknown\", \"Oncogenic mechanism was not established\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Functional loss-of-function studies and localization experiments demonstrated that NSD2 overexpression is required for myeloma cell proliferation and colony formation, and that it acts as a transcriptional repressor recruiting HDAC1/mSin3b, while breakpoint-variant isoforms show aberrant nucleolar localization.\",\n      \"evidence\": \"RNAi knockdown, gene targeting of translocated allele, co-immunoprecipitation, reporter assays, GFP-tagging and FRAP in MM cells\",\n      \"pmids\": [\"16197452\", \"17942756\", \"15677557\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Histone substrate specificity was unresolved\", \"Whether repression required catalytic activity was unclear\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Biochemical characterization revealed NSD2 possesses histone methyltransferase activity (H4K20 in cells, H3K4/H4K20 in vitro) and forms a repressive complex with HDAC1, HDAC2, mSin3a, and LSD1, while an alternatively transcribed isoform (RE-IIBP) showed H3K27 methyltransferase activity.\",\n      \"evidence\": \"In vitro methyltransferase assays, co-immunoprecipitation, Gal4-reporter assays, active-site mutagenesis\",\n      \"pmids\": [\"18156491\", \"18172012\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The primary physiological histone substrate (H3K36me2) had not yet been identified\", \"Specificity for H3K27 was later disputed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Discovery of NSD2 recruitment to DNA double-strand breaks via the γH2AX–MDC1 pathway, where it deposits H4K20me2 to facilitate 53BP1 accumulation, established a direct role in the DNA damage response.\",\n      \"evidence\": \"Co-immunoprecipitation of phospho-S102 NSD2 with MDC1 BRCT domain, laser-induced DSB recruitment, ChIP\",\n      \"pmids\": [\"21293379\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NSD2 also deposited H3K36me2 at DSBs was not shown\", \"Relative contributions to NHEJ vs HR were unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Multiple studies converged on H3K36me2 as NSD2's principal mark in cancer, showing that NSD2 overexpression causes global H3K36me2 gain with reciprocal H3K27me3 loss, directly activates TWIST1 to drive EMT, represses miR-126* to upregulate c-MYC, and is required for class switch recombination via 53BP1 recruitment to Igh switch regions.\",\n      \"evidence\": \"ChIP at target loci (TWIST1, miR-126*), isogenic gain/loss-of-function in prostate and MM cells, CSR assays, epistasis with EZH2\",\n      \"pmids\": [\"22797064\", \"22972034\", \"23241889\", \"23159737\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide distribution of H3K36me2 changes was not yet mapped\", \"Whether H3K36me2 was primary or secondary to other marks was debated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Discovery of the E1099K activating mutation in pediatric ALL, confirmed by mass spectrometry histone profiling, established that NSD2 gain-of-function through point mutations (not just translocation/overexpression) drives oncogenesis via H3K36me2 expansion.\",\n      \"evidence\": \"Mass spectrometry histone profiling across >1000 cancer genomes, shRNA knockdown, xenograft\",\n      \"pmids\": [\"24076604\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for E1099K hyperactivation was unknown\", \"Therapeutic vulnerabilities of NSD2-mutant cancers were unexplored\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Genome-wide ChIP-seq revealed that NSD2 overexpression redistributes H3K36me2 globally while paradoxically enhancing EZH2 recruitment at specific loci, and that PHD domains mediate NSD2 chromatin recruitment and are required for these epigenetic changes and in vivo tumorigenesis.\",\n      \"evidence\": \"ChIP-seq in isogenic MM cell lines, PHD domain mutants, xenograft tumor regression\",\n      \"pmids\": [\"25188243\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PHD domains select target loci was unresolved\", \"3D genome consequences were not examined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Kinetic isotope effect measurements established that NSD2 catalyzes H3K36 dimethylation via an SN2 mechanism with a late asymmetric transition state, preferring dimethylation over monomethylation, while functional studies showed NSD2 is required for both NHEJ and HR and is regulated by CRL4Cdt2-dependent S-phase degradation.\",\n      \"evidence\": \"KIE measurements, quantum chemical modeling, NHEJ/HR reporter assays in isogenic MM lines, cell synchronization and degradation assays\",\n      \"pmids\": [\"26787850\", \"27109101\", \"26771714\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for nucleosome recognition was unknown\", \"How degradation is counteracted in cancer was unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"AKT-mediated phosphorylation at S172 was shown to stabilize NSD2 by blocking CRL4Cdt2-dependent degradation, creating a positive feedback loop through NSD2-driven RICTOR transcription that amplifies AKT/mTORC2 signaling in PTEN-null prostate cancer.\",\n      \"evidence\": \"In vivo PTEN-null mouse prostate cancer model, phosphorylation mapping, co-immunoprecipitation, ChIP\",\n      \"pmids\": [\"28319045\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other kinases phosphorylate NSD2 at additional sites was unknown\", \"Therapeutic targeting of this feedback loop was not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"NSD2 was found to methylate non-histone substrates—PTEN at K349 (read by 53BP1 tudor domain for DSB repair) and STAT3 at K163 (activating angiogenic signaling)—while PARP1-mediated PARylation was discovered to inhibit NSD2 catalytic activity and chromatin binding, and NSD2 was shown to have catalytic-activity-independent scaffolding roles (with BRD4 at mesendodermal enhancers) and immune functions (Tfh cell differentiation via Bcl6).\",\n      \"evidence\": \"MS-based methylation mapping, site-directed mutagenesis, in vitro methylation assays, BioID proximity labeling, conditional knockout with genetic rescue, ChIP\",\n      \"pmids\": [\"31217297\", \"33742125\", \"31248990\", \"31235934\", \"31636135\", \"31649247\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full non-histone substrate repertoire was unknown\", \"Whether scaffolding and enzymatic functions are separable in vivo was untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Cryo-EM structure of NSD2 bound to the nucleosome revealed the autoinhibitory loop mechanism and how E1099K/T1150A mutations destabilize it, while a chemical probe (UNC6934) targeting the PWWP1 domain confirmed its role in reading H3K36me2 for chromatin retention and showed that PWWP1 antagonism redirects NSD2 to the nucleolus.\",\n      \"evidence\": \"Cryo-EM at near-atomic resolution, kinetic analysis, MD simulation, co-crystal structure of PWWP1/UNC6934, cellular imaging\",\n      \"pmids\": [\"34782608\", \"34782742\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length NSD2 structure including all reader domains was not resolved\", \"Whether PWWP1 antagonism is sufficient for therapeutic benefit was untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"NSD2 E1099K was shown to drive glucocorticoid resistance in pediatric ALL through H3K27me3 accumulation at the NR3C1 promoter (reversible by PRC2 inhibitors), while NSD2 cooperates with oncogenic KRAS to amplify transcriptional output in lung adenocarcinoma and functions as a requisite subunit of the AR/FOXA1 neo-enhanceosome at tumor-specific prostate cancer enhancers.\",\n      \"evidence\": \"CRISPR correction of E1099K, ChIP-seq, PRC2 inhibitor in PDX models, KRAS-driven LUAD mouse model, AR cistrome analysis with PROTAC degrader\",\n      \"pmids\": [\"34417224\", \"34555356\", \"39251788\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NSD2 inhibition synergizes with immunotherapy across cancers is unknown\", \"How NSD2 is recruited to AR/FOXA1 sites mechanistically is incompletely defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"NSD2 was established as required for adipogenesis (preventing H3K27me3-mediated silencing of C/EBPα/PPARγ targets), for spermatogenesis (maintaining H3K36me2 and regulating histone eviction via PSMA8 interaction), and for regulatory T cell homing to the maternal-fetal interface via CXCR4 upregulation.\",\n      \"evidence\": \"Conditional knockouts in preadipocytes, spermatogenic cells, and Tregs; ChIP-seq; co-immunoprecipitation; fertility/pregnancy phenotyping\",\n      \"pmids\": [\"29728617\", \"35736136\", \"35322173\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether NSD2's roles in these lineages are catalytic or scaffolding is incompletely resolved\", \"Tissue-specific NSD2 target gene programs are not fully defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Development of PROTAC degraders (UNC8153, UNC8732) demonstrated that targeted NSD2 degradation reduces H3K36me2, suppresses MM cell adhesion/proliferation, and reverses drug resistance in NSD2-mutant ALL, validating NSD2 as a druggable target.\",\n      \"evidence\": \"PROTAC degradation assays, FBXO22/cereblon dependency mapping, anti-proliferative assays in MM and ALL cells\",\n      \"pmids\": [\"36976643\", \"38965384\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo pharmacokinetics and toxicity profiles are unreported\", \"Selectivity over NSD1/NSD3 in therapeutic settings is uncharacterized\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Systematic CRISPR knockout of all H3K36 methyltransferases established a functional hierarchy (NSD1 > NSD2 > NSD3 > ASH1L) for intergenic H3K36me2 deposition, with NSD2 being the second-most important enzyme for broad intergenic domains.\",\n      \"evidence\": \"Individual and combinatorial CRISPR KO of K36MTs, ChIP-seq for H3K36me1/2/3, RNA-seq in mouse mesenchymal stem cells\",\n      \"pmids\": [\"39390582\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this hierarchy is conserved across all human cell types is untested\", \"Compensation mechanisms among NSD family members are incompletely understood\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full non-histone substrate repertoire, the structural basis for how reader domains (PHD, PWWP) coordinate locus-specific targeting genome-wide, whether catalytic and scaffolding functions can be therapeutically separated, and the in vivo efficacy and selectivity of NSD2-targeted degraders.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No full-length NSD2 structure with all reader domains\", \"Comprehensive non-histone substrate profiling has not been performed\", \"In vivo therapeutic index of NSD2-selective degraders or inhibitors is unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [4, 6, 14, 17, 23, 32, 38, 44]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [24, 25]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 2, 9, 20, 42]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [32, 33]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 33]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [3, 33]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [8, 15, 32]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [4, 14, 15, 17, 32, 44]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [8, 18, 22, 24, 31]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 2, 9, 20, 42]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 5, 14, 23, 34, 36]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [12, 28, 37, 41]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [19, 30]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [16, 29, 39]}\n    ],\n    \"complexes\": [\n      \"HDAC1/HDAC2/LSD1/mSin3a repressor complex\",\n      \"AR/FOXA1 neo-enhanceosome\"\n    ],\n    \"partners\": [\n      \"MDC1\",\n      \"PARP1\",\n      \"SMARCA2\",\n      \"NLRC5\",\n      \"BRD4\",\n      \"AR\",\n      \"HDAC1\",\n      \"PTEN\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}